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1 Abstract 
 
Chlamydia pneumoniae (Cpn) is a generally widely distributed respiratory 
human pathogen causing infections in the great majority of individuals once in 
a lifetime. Intensive and long lasting use of antibiotics is efficient in treating 
Cpn acute and persistent infections. Though, the majority of infections are 
asymptomatic or subclinical and especially persistent infection has been 
associated with a variety of chronic respiratory tract inflammatory diseases and 
cardiovascular diseases. Furthermore the development of antibiotic resistances 
has been observed in vitro which underlines the importance and advantages of 
a future prophylactic and therapeutic vaccine against acute and chronic Cpn 
infections.  
Given the essential role of TH1-type immune responses, primarily CD8+ 
T cells and CD4+ T cells but also humoral responses, in immunity to Cpn, 
potent induction of respective immune effector mechanisms is a requirement 
for successful vaccine design. The two-component adjuvant IC31® has been 
shown to efficiently induce CD8+ cytotoxic T lymphocyte (CTL) and CD4+ T 
helper (Th) responses to T cell antigens following their systemic 
administration. Additionally the efficacy of mucosal adjuvanticity following 
intra nasal immunization was demonstrated for IC31® using the protective Cpn 
antigen CopN.  
Further promising Cpn candidate antigens have been identified through 
the Antigen Identification Program (AIP®) by antibodies from infected/ 
exposed humans. During this study IC31®-induced cellular and humoral 
immune responses to 6 AIP®-discovered conserved recombinant Cpn antigens 
were evaluated in immunization and protection studies. Furthermore, the 
relevance of these antigens in Cpn infection in terms of cellular and humoral 
immunogenicity was assessed in infection primed immune response studies 
using BALB/c and C57BL/6 mice. Moreover, by applying immuno-
fluorescence microscopy the 6 candidate antigens could be located using sera 
from immunized animals. 
This study demonstrated the efficacy of IC31® in the induction of 
cellular and humoral responses in mucosal as well as systemic applications, 
supporting previous findings of a dominant TH1-type in a mixed TH1/TH2-type 
induction of immune responses. In addition two out of the 6 antigen candidates, 
namely CP0177-1 and CP0020-1, were found to substantially reduce the 
bacterial burden in Cpn challenged mice following intra nasal immunization in 
combination with IC31®. Moreover immunogenic epitopes of these two  
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antigens were identified by IFN-γ ELIspot and CFSE-CD3+-CD4+ flow cyto-
metry in protein immunized and infection primed BALB/c and C57BL/6 mice 
using peptide libraries.  
All together the results demonstrate the high potential of IC31® as a 
mucosal adjuvant and its application in nasal vaccines, as well as the efficiency 
of the AIP® technology for the identification of novel subunit vaccine 
candidates. 
 
2 Zusammenfassung 
 
Chlamydia pneumoniae ist ein generell weit verbreitetes, bakterielles, humanes 
Pathogen der Atemwege und verursacht ein- oder mehrmals pro Lebenszeit 
Infektionen bei der Mehrheit aller Menschen. Behandlungen von akuten und 
persistierenden Cpn Infektionen durch intensive und lang anhaltende 
Verabreichung von Antibiotika haben sich als effektiv erwiesen. Die meisten 
Infektionen verlaufen jedoch asymtomatisch oder in Form subklinischer 
Erkrankungen. Besonders persistierende Cpn Infektionen wurden in Zusam-
menhang mit chronischen inflammatorischen Erkrankungen der Atemwege 
sowie kardiovaskulären Erkrankrungen gebracht. Zusätzlich haben in vitro 
Studien gezeigt, dass Chlamydien Antibiotikaresistenzen entwickeln können. 
Gemeinsam unterstützen diese Tatsachen die Wichtigkeit und Vorteilhaftigkeit 
eines prophylaktischen und therapeutischen Impfstoffes, welcher sowohl vor 
akuten als auch vor chronischen Cpn Erkrankungen schützt.  
Die bewiesene zentrale Rolle von CD8+ T Zellen, aber auch CD4+ T 
Zellen und der humoralen Immunantwort vom Typ TH1, verlangt eine leis-
tungsfähige Stimulation der entsprechenden Effektormechanismen um bei der 
Entwicklung eines Impfstoffes gegen Cpn erfolgreich zu sein. Für das aus zwei 
Komponenten bestehende Adjuvans IC31® wurde bereits gezeigt, dass dieses 
ein wirkungsvoller Stimulator von CD8+ cytotoxischen T Lymphocyten (CTL) 
und CD4+ T Helfer (Th) Immunantworten in Folge systemischer 
Verabreichung von T-Zell Antigenen  ist. Des Weiteren wurde für IC31® die 
Effizienz des adjuvantiven Effekts in der mukosalen Anwendung, unter 
Verwendung des protektiven Cpn Antigens CopN, bewiesen.  
 Weitere vielversprechende Protein Antigene wurden im Verlauf des 
AIP® (Antigen-Identifizierungs-Programm) unter Verwendung  von humanen 
Seren, welche von infizierten oder von Krankheit regenerierten Patienten 
stammen, identifiziert. Während dieser Studie wurden die durch IC31® 
induzierten zellulären sowie humoralen Immunantworten gegen sechs im 
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Prozess des AIP® identifizierten, konservierten, rekombinanten Cpn Antigenen 
in Immunisierungsstudien und Protektionsstudien evaluiert. Zusätzlich wurde 
die Relevanz dieser Antigene im Verlauf einer Cpn Infektion, hinsichtlich 
zellulärer und humoraler Immunogenität, in durch Infektion angeregten 
Immunantworten von BALB/c und C57BL/6 Mäusen, untersucht. Außerdem 
konnte durch die Anwendung von Immunofluoreszenzmikroskopie und der 
Verwendung von aus immunisierten Mäusen stammender Seren die 
Lokalisation der besagten Antigene/Proteine bestimmt werden. 
 Diese Studie hat gezeigt, dass das Adjuvans IC31® eine überaus 
wirkvolle Induktion von antigenspezifischen zellulären und humoralen Immun-
antworten bewirkt und dies sowohl bei mukosaler als auch systemischer 
Verabreichung. Des Weiteren unterstützen die Ergebnisse die dominante 
Induktion einer Immunantwort vom Typ TH1 in einer gemischten TH1/TH2 
Immunantwort durch IC31®. Zusätzlich konnten aus den 6 Kandidaten 2 
identifiziert werden welche einen substanziellen, reduzierenden Effekt auf die 
Anzahl an Bakterien in den Lungen von infizierten Mäusen aufwiesen, wenn 
diese zuvor in Kombination mit dem Adjuvant IC31® intra nasal verabreicht 
wurden. Diese Kandidaten sind CP0177-1 und CP0020-1. 
Des Weitern konnten immunogene Epitope dieser beiden Proteine in 
immunisierten und infizierten BALB/c und C57BL/6 Mäusen durch IFN-γ 
ELIspot und CFSE-CD3+-CD4+ durchflusscytometrische Analysen identifiziert 
werden. 
 Zusammengefasst zeigen die Ergebnisse einerseits das große Potential 
des Adjuvanten IC31® in mukosalen Anwendungen oder als Bestandteil 
nasaler Impfstoffe und andererseits die hohe Effizienz des AIP® beim 
Auffinden neuartiger protektiver Impfstoffkandidaten. 
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3 Introduction 
 
3.1 Chlamydia pneumoniae 
 
Chlamydia pneumoniae (Cpn) is an obligate intracellular eubacterium that 
belongs to the Gram-negative group of bacteria. Cpn is one of the two species 
(spp.) in the family of the Chlamydiaceae that are common pathogens in 
humans and was first isolated in 1965 from the conjunctiva of a Taiwanese 
child participating in a trachoma vaccine trial [10]. The other species is 
Chlamydia trachomatis. The species Cpn consists of one human biovar 
(TWAR) and two animal biovars of which one infects horses (biovar equine) 
and the other infects frogs [1] and koalas (biovar koala [2]).  The genome size 
is rather small with approximately 1.2 Mbp [3].  
C. pneumoniae can be morphologically distinguished from other 
Chlamydia by its pear-shaped structure of elementary bodies (EB) and lose 
outer membrane [4]. Interestingly not all Cpn isolates possess pear-shaped 
elementary bodies as a characteristic feature [5-8]. Accordingly the presence of 
a large periplasmic space between the cytoplasm and the outer membranes, 
which is not seen in other chlamydial species, was demonstrated by scanning 
electron microscopy in Cpn elementary bodies [9, 11]. Chlamydia pneumonia, 
as other Gram-negative bacteria, has LPS in its cell membrane. The LPS is 
present in both elementary bodies and reticulate bodies (RB). Chlamydial LPS 
is a genus-specific group of antigens and therefore suitable as a marker for 
chlamydial infection [20].  
In distinction from other Gram-negative bacteria Chlamydia do not 
have peptidoglycan in the periplasmic space [22, 23], although the genes for 
the synthesis are present [3, 21] and chlamydial growth has shown to be 
sensitive to penicillin [24]. 
All Chlamydia replicate in a biphasic developmental cycle inside eu-
karyotic host cells. The smaller extracellular elementary body represents the 
metabolically inactive but infective stage of the developmental cycle. The 
primary step in chlamydial entry, which occurs minutes after infection, is the 
attachment of the EB to the host cell. This process of entry has been described 
to be mediated by a complex network where the proteins chemokine C-X-C 
motif receptor 7 (CXCR7), integrin beta 2 (ITGB2), platelet-derived growth 
factor beta polypeptide (PDGFB), vascular endothelial growth factor (VEGF), 
vascular cell adhesion molecule 1 (VCAM1), and GTP binding protein play a 
key role [12]. Uptake of the EB by endocytosis is highly dependent on the 
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reorganization of the actin cytoskeleton. Various different signaling pathways 
involved in actin dynamics and reorganization have been shown to be targeted 
by Chlamydia by inducing tyrosine phosphorylation of regulatory proteins. 
Examples are the PI3-kinase (PI3K) and MEK-ERK kinases and the Rho 
family of GTPases [13-16]. The differentiation of chlamydial EBs to reticulate 
bodies (RB) occurs at 8-12 hours post infection inside a protected vacuole, 
which is called an inclusion [16]. 
Cpn actively inhibits phagosome-lysosome fusion [40] and promotes 
the association with exocytic vesicles avoiding intracellular killing in this way 
[39]. Additional beneficial modulations for chlamydial survival inside the host 
are inhibition of apoptosis in macrophages [41] and epithelial cells [42] and 
down regulation of the expression of the major histocompatibility complex 
class I and class II molecules [43]. 
The intracellular form, the reticulate body, is metabolically active, 
replicates, but is not infectious. Between 12-48 hours post infection the RBs 
replicate inside the inclusion. RBs are highly dependent on the supplement-
ation of iron, amino acids and energy in form of ATP by the host cell [17, 18].  
After several rounds of multiplication, the RBs differentiate back into 
infectious EBs. An intermediate state which is called the intermediate body 
(IB) is present during the transition from the chlamydial RB to the EB. 
At 72- 92 hours post infection, when the replication of Chlamydia is 
complete, infectious EBs are released. Two different mechanisms by which 
EBs leave the host cell have been described for Chlamydia trachomatis. The 
first one is lysis of the host cell by rupture of the inclusion at the cell 
membrane in a sequential process [19]. The second way of exiting is called 
extrusion. Chlamydial extrusion leaves the host cell intact. Only a portion of 
the Chlamydia-containing vacuole is pinched-off and infectious EBs are 
released during this process. An intact part of the inclusion remains inside the 
host cell. Extrusion has been suggested to also play a role in chlamydial 
persistence [19]. The persistent state of chlamydial infection is thought to be an 
incomplete developmental cycle whereby Chlamydia are capable of causing 
long-term infection ranging for month or years in the absence of treatment. 
Low iron and tryptophan concentrations as well as antibiotic treatment are 
known inducers of persistence [18, 25]. In vitro IFN-γ treatment has become a 
common method to induce persistence through its activation of the host 
tryptophan-degrading enzyme indoleamine 2, 3-dioxygenase (IDO) which 
leads to the inability of Cpn RBs to differentiate into EBs [18].  
A variety of antibiotics, such as tetracyclines, macrolides, rifamycines 
and erythromycin have been shown to be effective in treating Cpn infection 
[11, 26]. Though, antibiotic treatment is recommended to be intensive and long 
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lasting (3-4 weeks) in order to avoid reinfection by persistent bacteria which is 
even more difficult to treat effectively [26]. It has been seen that Chlamydia 
can develop antibiotic resistance in vitro. Therefore antibiotic resistance might 
become a problem in future treatment [33-36]. 
Chlamydia pneumoniae as a disease is generally widely distributed. 
Seroepidemiologic studies showed an antibody prevalence of 50% at an age of 
20 years and 70-80% at an age of 60-70 years [26]. The human pathogen Cpn 
is transmitted via aerosol droplets and respiratory secretions from person to 
person. The majorities of Cpn infections are asymptomatic or subclinical mild 
upper respiratory tract infections. Cpn is the causative agent of diseases such as 
pneumonia, acute bronchitis, common cold, persistent cough, pharyngitis, 
sinusitis and otitis media [27]. In addition, Cpn infection has been associated 
with a variety of chronic respiratory tract inflammatory diseases. Examples are 
chronic bronchitis and chronic obstructive pulmonary disease (COPD) as well 
as sarcoidosis [27]. Several studies indicate an association between Cpn and 
asthma [28]. Finally, C. pneumoniae has been associated with cardiovascular 
diseases, especially with atherosclerosis which is based on data from 
seroprevalence studies and by the direct detection of the organism within 
artheromatous plaques [29, 30-32]. 
Studying the mechanisms underlying protection against Cpn infection 
revealed that protective immunity strongly depends on the viability of the T 
cell compartment. CD4+ T cells and CD8+ T cells have been found at the site of 
infection in humans and in mice. Both CD4+ T cells and CD8+ T cells 
contribute to protection mainly through the secretion of the type 1 cytokine 
IFN-γ.  Several studies showed that IFN-γ secreting CD4+ T cells of the TH1 
subset can inhibit Chlamydia replication [46]. Furthermore, IFN-γ levels 
produced by macrophages during Cpn infection were efficient in reducing 
bacterial loads which underlines the importance of this cytokine [48]. 
Additionally the absence of IFN-γ dramatically increased the bacterial burden 
in murine challenge studies [47].   
Murine depletion models of CD4+ T cells and CD8+ T cells showed a 
deteriorated course of infection in both cases, but especially CD8+ T cells have 
been shown to play a critical role in protective immunity to Cpn infection [38]. 
Pathogen specific CD8+ T cells which exert an ex vivo cytolytic effector 
function have been isolated from Chlamydia trachomatis (Ct) and Cpn 
infection models. Furthermore adoptive transfer experiments of Ct specific 
type 1 cytokine-producing CD8+ cytotoxic T cells were partially protective 
[38]. Acquired immunity to Cpn infection was found to be dominantly 
dependent on CD8+ T cells in a murine infection model [44, 45]. This findings 
stand in contrast to data from a Ct infection model, where the effect of CD4+ T 
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cell depletion on the course of disease was more pronounced compared to 
CD8+ T cell depletion. However, as CD4+ T cells are often required for the 
induction and maintenance of a functional CD8+ T cell compartment the role of 
CD8+ T cells should not be underestimated [38]. The importance of the CD8+ T 
cell population in protection against Cpn infection is not surprising given the 
intracellular nature of this pathogen and the MHC class I presentation of 
peptides commonly derived from the cytosol to CD8+ T cells. However, MHC 
class I molecules can also present peptides originating from exogenous soluble 
or cell-associated proteins, including antigens which are not secreted from 
intravacuolar and cytosolic pathogens by cross-presentation. MHC class I 
presentation of antigens to CD8+ T cells can be enhanced by the interaction 
with B cells across professional antigen-presenting cells (pAPC) such as 
dendritic cells (DC), by their Fc receptor mediated uptake of antigen bound by 
IgG2a or IgA. In fact, mice lacking both CD8+ T cells and B cells show a 
dramatically increased chlamydial burden compared to CD8+ T cell depletion 
alone. Furthermore the depletion of IgA alone and in combination with the 
depletion of CD8+ T cells leads to an increased bacterial burden in murine 
challenge models which underlines the importance of this immunoglobulin in 
protection against infection by the respiratory pathogen Chlamydia 
pneumoniae [49, 50]. 
 
3.2 Antigen Identification Program (AIP®) 
 
The identification of few protective components from the entirety of molecules 
present in a pathogen as well as the validation of the immune response against 
any candidate antigen are generally complex and time consuming tasks in the 
design of a subunit vaccine. The approach combining the advantages of the 
post-genomic era and serological antigen identification is an effective way to 
meet these challenges. This process has been first applied to Staphylococcus 
aureus by the use of a small-fragment genomic-surface display library and 
antibodies from human serum [51].  
Intercell’s AIP® technology uses human sera from previously exposed 
and diseased individuals as primary screening selection criteria on a genome-
wide basis. The antigen screening is performed against a bacterial surface 
display library of E. coli outer membrane proteins LamB and FhuA [52-54] 
thereby providing a subset of all genome-encoded proteins of a pathogen that 
are expressed in vivo and induce antibodies in humans. The validation 
procedure in general includes PCR studies to confirm the conservation of the 
encoding gene in various clinical isolates, peptide ELISA assays to prove the 
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immunogenicity in humans and FCM analyses to show that the antigen is 
localized on the surface of the pathogen. Bactericidal assays are performed to 
test the functionality of the antibodies directed against a particular antigen in 
animal models. This technology has been successfully applied to various 
human pathogens such as S. aureus, S. epidermidis, S. pneumoniae, S. 
agalactiae, S. pyogenes [52], Enterococcus faecalis, K. pneumoniae, Borrelia 
spp., ETEC, Shigella, Campylobacter jejuni, non-typable Haemophilus 
influenzae, Moraxella catarhalis and Chlamydia pneumoniae. 
In the case of Cpn the AIP® technology has led to the identification of 
84 antigenic proteins out of 1052 open reading frames. From those 34 high 
priority antigens were selected on the basis of conservation in different clinical 
isolates. 6 out of those high priority antigens were selected for the evaluation of 
IC31®-induced immune mechanisms during this study. The criteria by which 
these antigens were chosen included conservation, quality of recombinant 
protein expression, solubility and the fact of being uncharacterized hypothetical 
proteins. 
 
3.3  Chlamydia outer protein N (CopN) 
 
CopN is a chlamydial type III secreted protein that is also present in the 
inclusion membrane and inclusion body as demonstrated by immuno-
fluorescence staining using sera obtained from mice immunized with the 
recombinant protein [55]. As an equivalent to Yersinia YopN, CopN is 
described to be the lid of the type III secretion system (TTSS) apparatus 
regulating the gating function of type III secretion [56].  
Regarding the function of CopN, heterologous expression of the protein 
in mammalian and yeast cells induced a cell cycle arrest at the G2/M phase, 
possibly due to reorganization of the cytoskeleton [57]. Additionally, the 
essential role of CopN in chlamydial growth was demonstrated by functional 
knock-out of the protein leading to the inhibition of Cpn growth in infected 
cells.  Immunization studies with CopN in mice and hamster showed a 
protective effect against Cpn challenge when administered via the intra nasal or 
intra peritoneal route [58, 59]. The protective effect was even more pronounced 
when CopN was delivered in combination with E.coli heat-labile toxin [59]. 
Previous in house experiments further showed a protective effect of CopN 
when BALB/c mice where immunized intra nasally with recombinant CopN in 
combination with IC31® as an adjuvant. Resembling a potent Chlamydia 
vaccine candidate recombinant CopN was used as a control in immunological 
assays and Cpn challenge experiments throughout this study.  
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3.4 Chlamydia Major Outer Membrane Protein (MOMP) 
 
The major outer membrane protein of Chlamydia is a 40 kDa immunodominant 
protein located on the surface of chlamydial EBs and RBs. MOMP has been 
well characterized as a porin and an adhesin. Further, MOMP is used to 
determine chlamydial genus and species specificity. Sequence analysis of 
MOMP in different chlamydial species has revealed a structurally similar gene 
organization containing conserved regions [11]. As MOMP induces 
neutralizing antibodies and T cell responses [60, 61], it is regarded as one of 
the most promising vaccine candidates for an anti-chlamydial subunit vaccine. 
The protective effect after immunization with MOMP was demonstrated in 
various studies in mice using the Ct [62-64] and the Cpn [49, 65] model. This 
results where further confirmed by in house Cpn intra nasal challenge studies 
where recombinant MOMP was intra nasally administered either alone or in 
combination with cholera toxin (CT) as well as IC31® as an adjuvant. Besides 
recombinant CopN, MOMP was used as an additional control antigen during 
this study. 
 
3.5 Adjuvants 
 
The two-component adjuvant IC31® is composed of a synthetic immuno-
stimulatory oligodeoxynukleotide containing deoxy-inosine/deoxy-cytosin 
repeats (ODN1a; 5’ICICICICICICICICICICICICIC-3’) and the cationic 
peptide KLKL5KLK (KLK). The immunostimulatory effects of IC31® 
originate from the immunopotentiating effects of KLK, stimulating protein-
specific type-2 adaptive immune response after prime-booster immunizations 
[67] and enhancing antigen uptake through dendritic cells by binding and 
integrating into the membrane, specifically targeting lipid rafts [66]. The 
specificity of activation is supported by the upregulation of CD40, CD80 
(B7.1), CD86 (B7.2) and IL12p40 only in dendritic cells associated with IC31® 
[68]. Additionally, KLK mediates depot formation of antigen injected in 
combination with IC31® at the injection site which is of great advantage for 
sustained antigen and adjuvant release [67].  
ODN1a, as second part of IC31® has its adjuvantive effect by signaling 
via TLR9 and MyD88, thereby activating NF-κB and initiating immune 
responses. These responses include a specific type 1 dominated mixed type 1 
and type 2 and cytotoxic T cell adaptive immune response as well as IgG1 and 
IgG2 B cell responses. In addition to the enhancement of antigen-specific T 
 - 9 -
cell responses in mice this adjuvantive effect on T cell responses was also 
observed in monkeys and humans. Furthermore, a variety of toxicological 
studies did not show any toxic effect of IC31® [69]. Recent studies using CopN 
as a model antigen and IC31® as an adjuvant in a murine mucosal model 
showed a strong antigen and epitope specific local and systemic T cell response 
in terms of IFN-γ secretion, and enhanced antigen specific IgG titers (Zimmel. 
D, 2009; unpublished data). 
In some experiments chlora toxin (CT) was used as an adjuvant in 
combination with MOMP. Cholera toxin is a common adjuvant for studying 
mucosal immunity in murine models due to its strong immunostimulatory 
effects. However, CT is not applicable to humans because of its toxic 
properties [70]. 
 
3.6 Mucosal Immunity in the Lung and Nasal Vaccination 
 
The mucosal immune system includes the gastrointestinal tract, the upper and 
lower respiratory tracts, the urogenital tract as well as exocrine glands 
associated with these organs such as the pancreas, the conjunctivae and 
lachrymal glands of the eye, the salivary glands and the lactating breast.  In 
total it covers an area approximately 200 times larger than the skin of an adult. 
The functions of the mucosal immune system involve the protection of the 
mucous membranes against colonization and invasion by potentially harmful 
microbes, the prevention of the uptake of unprocessed antigens originating 
from ingested food, inhaled particles or commensal microorganisms and the 
prevention of harmful immune reactions to those antigens [71].  
Mucosal surfaces are protected from the environment by a thin layer of 
epithelial cells where most pathogens actually invade. Protection is maintained 
by the epithelium itself resembling a physical barrier, by secretion of mucins 
and antimicrobial proteins and a highly specialized innate and adaptive 
immune system. Besides acting as a physical line of defense, epithelial cells act 
as sensors recognizing common components of dangerous microbes by pattern-
recognition-receptors (PRR) such as Toll-like receptors (TLR). Through the 
secretion of cytokines and chemokines epithelial cells respond and signal to 
underlying mucosal cells such as DCs and macrophages in order to initialize 
nonspecific innate immune defenses and specific adaptive immune responses 
[71, 72]. 
Antigen-specific immune responses are initiated at so called microfold 
cells (M cells) located in the epithelium and above follicles of the mucosa-
associated lymphoid tissue (MALT). At this site all cells which are required for 
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the generation and regulation of an immune response, T cells, B cells and 
professional antigen-presenting cells (pAPC), can be found. Furthermore, DCs 
can actively capture antigen and as well as other pAPCs directly present those 
to T cells present at the inductive site.  
 IgA is the prevalent type of antibody in the mucosal immune system, 
and is produced in a ratio of IgA1 to IgA2 of 3:2 almost exclusively as a 
dimmer by plasma cells expressing the mucosal homing receptor α4:β7 and/or 
α4:β1 as well as the chemokine receptors CCR9 and/or CCR10. However, 
homing of plasmablasts in the airways depends on the expression of CD62L, 
α4:β1, CCR7 and CCR10. Subsequent production and secretion by B cells, IgA 
is transported from the inner side of the epithelial wall into the lumen by 
transcytosis through epithelial cells expressing the polymeric immunoglobulin 
receptor (poly-Ig receptor). In humans, isotype switch of B cells to IgA 
production and differentiation to IgA secreting plasma cells was demonstrated 
to be dependent on transforming growth factor (TGF)-β, IL-10 and IL-4 [78]. 
The functions of secretory IgA at mucosal surfaces include 
neutralization of pathogens and toxins either on the mucosal surface or inside 
endosomes and the binding of antigens in the lamina propria enabling export 
into the lumen [71, 73]. Opsonization and antibody-dependent cell-mediated 
cytotoxicity (ADCC) by IgA are supposed to be of minor importance compared 
to the effector mechanisms described above. 
In the respiratory tract nasopharynx-associated lymphoid tissue (NALT) 
and bronchus-associated lymphoid tissue (BALT) are important inductive sites 
for the generation of mucosal immunity. The common mucosal immune system 
(CMIS) connects these inductive sites with mucosal tissues and allows 
communication between organized mucosa-associated lymphoid tissues, 
thereby enabling the generation of antigen-specific TH2-cell-dependent IgA 
responses, TH1-cell and cytotoxic T lymphocyte (CTL)-dependent immune 
responses that also act at distant sites of the induction as well as the induction 
of a systemic immune response [72]. Regarding the T cell environment present 
in NALT, mRNA characterization of TH1 and TH2 cytokines in murine NALT 
CD4+ T cells revealed a prevalent TH0 profile, indicating the capability of these 
cells for becoming TH1 and TH2 cells by antigen exposure of the nasal tract. 
The commitment for a specific type of T cell response was shown to be 
dependent on the type of nasally administered antigen and adjuvant [74-77]. 
 In general, nasal vaccination has shown to be an efficient way for the 
stimulation of the respiratory immune system eliciting both, humoral and cell 
mediated responses in mucosal and systemic immune compartments [74-77]. 
Further advantages of nasal immunization include the generation of cross-
protective immunity in the reproductive tract as well as in the upper respiratory 
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tract, the need of a smaller dose of antigen in comparison to oral vaccination, 
and the redundancy of injection and trained medical personnel. 
 
 
4 Results 
 
4.1 Antigen purification 
 
Based on results obtained by the Antigen Identification Program® 6 conserved 
uncharacterized hypothetical proteins were selected for recombinant expression 
in E. coli, and were subsequently isolated by gravity column affinity puri-
fication. The selected candidate proteins were: CP0529, CP0177-1, CP0020-1, 
CP0504, CP0409 and CP0879. For the evaluation of IC31®-induced immunity 
and immunogenicity these proteins were chosen to build the basis for intra 
nasal and intra peritoneal immunization studies, intra nasal immunization-
challenge studies as well as infection primed immune response studies. In order 
to ascertain an optimal quality of soluble recombinant protein for in vivo and in 
vitro application following parameters were implicated respecting the final 
solution of recombinant C. pneumoniae proteins: LPS ≤ 200 EU/ml, Tween20 
≤ 0.1%, protein concentration ≥ 0.55 mg/ml, L-Arg concentration < 100 mM. 
The applied procedures for antigen purification are described in section 6.1, 
materials and methods. 
Figure 1: SDS-PAGE, Western Blot; Purification of CP0529: CL (crude lysate), SOL 
(soluble fraction), INSOL (insoluble fraction), EA (eluate under native conditions), EEE 
(eluate under denaturating conditions), p.d. (post dialysis). Procedure of protein purification 
is shown chronologically from left to right. 
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The procedure for the isolation of CP0529 is shown in figure 1. CP0529 has 
the size of 231 amino acids (aa) containing 1 cysteine (cys) and a molecular 
weight of 25.0 kDa. As found by using the protein basic local alignment search 
tool (BLAST) provided by the National Center of Biotechnology Information 
(NCBI) the ortholog in Ct is the uncharacterized hypothetical protein CT181. 
CP0529 was purified from the soluble fraction of recombinant E. coli lysate. 
Dialysis of the fraction eluted under native conditions was performed against 
50 mM TrisHCl, pH 8.0, 150 mM NaCl. The final preparation of recombinant 
CP0529 contained 1.51 mg/ml protein and 23.78 EU/mg LPS. Size exclusion 
chromatography (SEC) revealed that 95.5% of the protein was present as a 
monomer in the final buffer.  
 As CP0529, the recombinant protein CP0177-1, consisting of aa 1-380 
of CP0177, containing 2 cys and with a molecular weight of 40.8 kDa, also 
showed to be expressed in the soluble fraction. The solution used for 
immunizations and in vitro stimulation was prepared in 50 mM TrisHCl,  
pH 8.0, 150 mM NaCl and contained 1.68 mg/ml protein and 53.98 EU/mg 
LPS. SEC analysis showed 83.8% of protein to be present as a monomer in 
solution. Figure 2 shows the purification procedure of CP0177-1 chrono-
logically. Interestingly CP0177-1 aberrantly migrated at approximately 60 kDa  
 
Figure 2: SDS-PAGE, Western Blot; Purification of CP0177-1: CL (crude lysate), SOL 
(soluble fraction), INSOL (insoluble fraction), FT (flow through), EA (eluate under native 
conditions), EEE (eluate under denaturating conditions), p.d. (post dialysis), filt. (0.2 µm 
filtered). Procedure of protein purification is shown chronologically from left to right. 
 
 
in SDS-PAGE and western blot while it has a molecular weight of 40.8 kDa, a 
property of this protein that was also seen in orthologs [81]. However, for 
validation of the protein identity N-terminal sequencing was performed (Alta 
 - 13 -
Bioscience, University of Birmingham) which confirmed the purification of 
CP0177-1. 
The ortholog of Cpn CP0177 in C. trachomatis is CT456. CT456 
protein is also called translocated actin-recruting phosphoprotein (TARP) and 
was found to be present in C. pneumoniae, C. caviae, C. muridarum and C. 
trachomatis EBs [79]. Furthermore, Ct TARP was demonstrated to be a type 
III-secreted protein that is involved in the recruitment of actin by targeting host 
small GTPases and inducing F-actin reorganization at the entry site of the 
chlamydial EB [80]. In contrast to its orthologs Ct TARP possesses several 
tyrosine-rich repeats in its N-terminal region which become tyrosine-
phosphorylated inside the target cell. However, tyrosine phosphorylation was 
shown not to be involved in the process of actin recruitment nor was it essential 
for infection of target cells by Chlamydia [79].  
 
 
B 
A 
Figure 3: SDS-PAGE, Western Blot; A: Purification of CP0020-1; B: Purification of 
CP0879: CL (crude lysate), SOL (soluble fraction), INSOL (insoluble fraction), FT (flow 
through), EEE (eluate under denaturating conditions), p.d. (post dialysis), filt. (0.2 µm 
filtered), conc. (post centrifugal concentration). Procedure of protein purification is shown 
chronologically from left to right. 
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The C-terminal domain of TARP contains the greatest sequence similarity 
between orthologs. Interestingly all TARP orthologs contain an actin-binding 
helix and proline-rich oligomerization domain in the conserved C-terminal 
region [79].  In 2009 J. Wang et al demonstrated in a murine C. muridarum 
vaginal infection model the induction of TARP specific cellular and humoral 
immune responses. 
Furthermore, intra muscular immunization of BALB/c mice with Ct 
TARP adjuvanted with CpG-incomplete Freud’s adjuvant (IFA) led to the 
reduction of bacterial loads in the lower genital tract of challenged mice and 
attenuated inflammatory pathologies in the fallopian tube tissue [81]. 
CP0020-1 as well as candidate protein CP0879 were isolated under de-
naturating conditions from purified inclusion bodies after recombinant 
expression in E. coli. CP0020-1 consists of amino acid 2-418 of Cpn CP0020, 
and has a molecular weight of 46.9 kDa. The sequence contains 3 cys. The 
ortholog in Ct is CT620.  
Recently genetic vaccination using the vector pCMVi-UB carrying the 
CP0020 gene was shown to protect mice from death in a high dose Cpn 
challenge study, but did not reduce disease or bacterial lung loads [82].  
The purification procedure of CP0020-1 and CP0879 are shown in 
figure 3A and 3B respectively. CP0020-1 was stepwise dialyzed against 500 > 
250 > 100 mM L-Arg, 50 mM TrisHCl, pH 8.0, 150 mM NaCl, 0.1% 
Tween20. The final protein solution contained 1.26 mg/ml protein and 119.18 
EU/mg LPS. SEC analysis of the final CP0020-1 protein solution showed 
strong oligomerization with no monomers of CP0020-1 present. 
CP0879 protein has a molecular weight of 40.6 kDa and contains amino 
acids 2-343 of 343, 5 of these being cys. The protein solution which was eluted 
under denaturating conditions was stepwise dialyzed against 500 > 250 > 100 
mM L-Arg, 50 mM TrisHCl, pH 8.5, 150 mM NaCl, 0.1% Tween20. 
The CP0879 solution used for immunizations and in vitro stimulation 
contained 0.93 mg/ml protein and 182.58 EU/mg LPS. 100% of CP0879 were 
present as oligomers in the final solution, as assessed by SEC. Protein BLAST 
with the aa sequence of CP0879 did not reveal an ortholog in Ct.  
The sequential purification procedures for candidate proteins CP0504 
and CP0409 are shown chronologically in figure 4A and 4B respectively. Both 
proteins were purified under denaturating conditions from purified inclusion 
bodies.  
As proteins CP0504 and CP0409 showed to precipitate during dialysis 
using a variety of different buffer systems, these two candidates were subjected 
to refolding experiments. The procedure of refolding and subsequent isolation 
is described in section 6.1.6, materials and methods.  
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CP0504 protein has the size of 287 aa (5 cys) and a molecular weight of  
33.1 kDa. The ortholog of CP0504 in Ct is CT143, an uncharacterized 
hypothetical protein. The final protein solution of CP0504 contained  
2.01 mg/ml protein and 71.06 EU/mg LPS. The final buffer consisted of 50 
mM TrisHCl, pH 8.5, 150 mM NaCl, 100 mM L-Arg and 0.1% Tween20.  
5% of CP0504 in the final buffer were assessed to be present in monomers by 
SEC. 95% were present as strongly interacting oligomers which were not 
resolved during SDS-PAGE as can be seen in figure 4A. 
The ortholog of CP0409 in Ct is the uncharacterized hypothetical 
protein CT066. CP0409 consists of 171 aa (2 cys) and has a molecular weight 
of 20.6 kDa. The final preparation of CP0409 contained 0.58 mg/ml protein, 
5.38 EU/mg LPS and showed 100% oligomerization in SEC analysis. 
    
 
Figure 4: SDS-PAGE, Western Blot; A: Purification of CP0504; B: Purification of 
CP0409: CL (crude lysate), SOL (soluble fraction), IB (inclusion bodies), FT (flow 
through), EA (eluate under native conditions), EEE (eluate under denaturating conditions), 
p.d. (post dialysis), p. ref. (post refolding), p.c. (post centrifugal concentration), filt. (0.2 
µm filtered), Procedure of protein purification is shown chronologically from left to right. 
 
B 
 
 
A 
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Table 1 summarizes the properties of the 6 purified Cpn candidate antigens. In 
general, purification of recombinant His-tag proteins from the soluble fraction, 
by gravity column affinity purification, showed to be more efficient but led to a 
higher degree of contamination with co-isolated E. coli proteins. In contrast all 
candidate antigens purified from inclusion bodies showed a higher degree of 
purity but a stronger tendency for oligomerization.  
LPS contamination heavily varied regarding each different candidate 
protein, indicating the dependency of LPS binding to protein on the antigen 
itself and not the purification procedure. However, CP0529, CP0177-1, 
CP0020-1, CP0504, CP0409 and CP0879 could be successfully purified with 
keeping the limitations indicated in the beginning in mind. 
 
 
 CP0529 CP0177-1 CP0020-1 CP0504 CP0409 CP0879 
Annotation 
 
Conserved  
hypothetical  
protein 
 
Conserved 
hypothetical 
protein 
 
Conserved  
hypothetical  
protein 
 
Conserved  
hypothetical  
protein 
 
Conserved  
hypothetical  
protein 
 
Conserved  
hypothetical  
protein 
 
Homology/ 
Function 
 
Uncharacterized 
(CT181) 
 
TARP 
(CT456) 
 
Uncharacterized
(CT620) 
 
Uncharacterized
(CT143) 
 
Uncharacterized 
(CT066) 
 
Uncharacterized
(no ortholog  
in Ct) 
 
Solubility 
 
Soluble 
 
Soluble 
 
Insoluble 
 
Insoluble 
 
Insoluble 
 
Insoluble 
 
LPS 
 
23.78 EU/mg 
 
53.98 EU/mg 
 
119.18 EU/mg 
 
71.06 EU/mg 
 
5.38 EU/mg 
 
182.58 EU/mg 
Final buffer 
50 mM TrisHCl 
pH 8.0 
150 mM NaCl 
50 mM TrisHCl 
pH 8.0 
150 mM NaCl 
 
50 mM TrisHCl 
pH 8.0 
150 mM NaCl 
100 mM L-Arg 
0.1% Tween20 
 
50 mM TrisHCl 
pH 8.5 
150 mM NaCl 
100 mM L-Arg 
0.1% Tween20 
 
50 mM TrisHCl 
pH 7.0 
150 mM NaCl 
100 mM L-Arg 
0.1% Tween20 
 
50 mM TrisHCl 
pH 8.5 
150 mM NaCl 
100 mM L-Arg 
0.1% Tween20 
 
Estimated 
yield 
 
12.5 g biomass: 
~40 mg 
(1.51 mg/ml) 
 
34.2 g biomass: 
~150 mg 
(1.68 mg/ml) 
 
1g IBs 
~20 mg 
(1.26 mg/ml) 
 
2 g IBs: 
~18 mg 
(2.01 mg/ml) 
 
2 g IBs: 
~ 5 mg 
(0.58 mg/ml) 
 
200 mg IBs: 
~ 10 mg 
(0.93 mg/ml) 
 
% 
oligomers 
4.5% 16.2 % 100% 95% 100% 100% 
 
  Table 1: Characteristics and purification profile for selected Chlamydia pneumoniae  
  candidate antigens 
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4.2 Immunogenicity of selected Chlamydia pneumoniae antigens 
 
For the evaluation of Cpn candidate antigens, respecting cellular and humoral 
immune responses induced by immunization of BALB/c mice either with the 
Chlamydia antigen alone or in combination with the adjuvant IC31®, IFN-γ 
ELIspot, IL-4 ELIspot, CD154 FCM and ELISA assays where the chosen 
readout.  The basis for this selection built the documented importance of type I 
interferon, especially IFN-γ production, primarily by CD4+ and CD8+ T cells in 
protective immune responses directed against Chlmaydia pneumoniae [46, 47]. 
Additionally, secretion of the type II cytokine IL-4 was assessed by ELIspot in 
order to measure the induction of TH2-type T cell responses.  
Flow cytometric analysis of antigen induced expression of the cell 
marker CD154, which is also called CD40 ligand (CD40L), was assessed in 
CD4+ T cells purified from lungs and spleens of immunized animals. 
Expression of CD154 on CD4+ T cells is an important effector function of this 
cell type, as CD40 signaling has been implicated in the activation and 
differentiation of APCs including DCs [87, 88], B cells [83] and macrophages 
[84, 86]. Therefore CD40-CD40L interaction plays a central role in almost all 
immunological processes. Factors that influence the expression of CD154 on T 
cells will for this reason influence the activation and differentiation of APCs, a 
fundamental process in the development of an effective adaptive immune 
response. Antigen specific ELISA was chosen for the assessment of serum IgG 
and serum IgA titers which were induced by intra nasal and parental im-
munization.  
 
4.2.1 Antigen induced IFN-γ responses 
 
Immunizations were performed as described in section 6.6, materials and 
methods. IFN-γ responses to candidate antigens CP0529 and CP0177-1, 10 
days post 3rd intra nasal immunization, following ex vivo restimulation with the 
indicated amounts of protein, are shown in figure 5. The results demonstrate 
the absence of immunogenicity for candidate CP0529 in terms of IFN-γ 
response following i.n. delivery of the antigen, either with or without adjuvant. 
In contrast experimental groups immunized with the protein CP0177-1 in 
combination with IC31® showed an intense IFN-γ response to restimulation 
with the antigen, while IFN-γ secretion was not restimulated in the group 
immunized with antigen alone. Regarding the recombinant proteins CP0020-1 
 - 18 -    
and CP0504, as well as candidates CP0409 and CP0879, ex vivo restimulation 
induced IFN-γ responses are shown in figures 6 and 7 respectively.  
 
Figure 5: IFN-γ ELIspot; CP0529, CP0177-1: Mice were immunized 3 times i.n. in a distance 
of each 14 days. 10 days post 3rd immunization 3 mice per group were sacrificed and IFN-γ 
secretion by splenic lymphocytes in response to ex vivo restimulation was assessed. Mean ± 
SD. SFC (spot forming cells). 
 
 
Figure 6: IFN-γ ELIspot; CP0020-1, CP0504: Mice were immunized 3 times i.n. in a distance 
of each 14 days. 10 days post 3rd immunization 3 mice per group were sacrificed and IFN-γ 
secretion by splenic lymphocytes in response to ex vivo restimulation was assessed. Mean ± 
SD. SFC (spot forming cells). 
 
Interestingly, candidate proteins CP0020-1 and CP0504 showed a 
strong response in terms of IFN-γ production when administered intra nasally 
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to mice, either in combination with IC31® or when the antigen was delivered 
alone, while the production of IFN-γ was more pronounced in groups 
immunized in combination with the adjuvant. Furthermore CP0020-1 showed 
the tendency to a more balanced response in groups which had received this 
antigen, while IFN-γ response induced by CP0504 ex vivo restimulation was 
more differentiated in experimental groups that had been immunized with this 
protein. 
 The analysis of IFN-γ responses, induced by intra nasal immunization 
with the recombinant protein CP0879, revealed a strong antigen specific 
response which was dependent on the adjuvant IC31® (figure 7). Furthermore, 
the usage of CP0879 as an irrelevant stimulus in naïve and IC31®-alone groups 
showed a relatively high number of IFN-γ SFC. In contrast, groups immunized 
with CP0409 responded to ex vivo restimulation equally, indicating 
independence of immunogenicity on the adjuvant in intra nasal immunizations. 
However, IFN-γ responses to CP0409 were weak compared to CP0879 
indicating poor general immunogenicity of CP0409. Additionally there is to 
add that immunogenicity in terms of IFN-γ secretion of CP0879 and CP0409 
were only assessed 10 days after 2nd intra nasal and intra peritoneal 
immunizations due to company internal reasons. What the results would have 
looked like after 3 immunizations can only be speculated about, especially 
when keeping the depot forming property of IC31® in mind which could 
potentially lead to a more pronounced, delayed adjuvantive effect after 3 doses.  
 
 
Figure 7: IFN-γ ELIspot; CP0879, CP0409: Mice were immunized 2 times i.n. in a distance of 
each 14 days. 10 days post 2nd immunization 3 mice per group were sacrificed and IFN-γ 
secretion by splenic lymphocytes in response to ex vivo restimulation was assessed. Mean ± 
SD. SFC (spot forming cells). 
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A significant increase of IFN-γ production, when comparing ex vivo 
restimulated responses post 2nd with post 3rd immunization time points, was 
especially observed in groups immunized with IC31®, but was less pronounced 
in groups immunized with protein alone (own observations). 
 
 
Figure 8: IFN-γ ELIspot; CP0529, CP0177-1, CP0020-1, CP0504: Mice were immunized 3 
times i.p. in a distance of each 14 days. 10 days post 3rd immunization 3 mice per group were 
sacrificed and IFN-γ secretion by splenic lymphocytes in response to ex vivo restimulation was 
assessed. Mean ± SD. SFC (spot forming cells) 
 
 
Figure 9: IFN-γ ELIspot; CP0879, CP0409: Mice were immunized 2 times i.p. in a distance of 
each 14 days. 10 days post 3rd immunization 3 mice per group were sacrificed and IFN-γ 
secretion by splenic lymphocytes in response to ex vivo restimulation was assessed. Mean ± SD 
SFC (spot forming cells). 
 - 21 -
In general, intra peritoneal immunizations with the selected antigens, either 
with or without adjuvant, led to similar responses regarding IFN-γ production 
as the ones obtained by intra nasal immunizations (figure 8 and figure 9). 
The protruding differences were a universally stronger stimulation of 
IFN-γ production in terms of SFC, immunogenicity of CP0529 which was 
more pronounced in the group immunized in combination with IC31® and 
which was not observed after intra nasal immunizations as well as reduced 
immunogenicity of CP0409 when administered without adjuvant. 
 
4.2.2 Antigen induced IL-4 responses 
 
 
Figure 10: IL-4 ELIspot; CP0529, CP0177-1, CP0020-1, CP0504 post 2nd immunization; Mice 
were immunized 2 times i.p. in a distance of each 14 days. 10 days post 2nd immunization 2 
mice per group were sacrificed and IL-4 secretion by splenic lymphocytes in response to ex 
vivo restimulation was assessed. Mean ± SD. SFC (spot forming cells). 
 
IL-4 responses to ex vivo restimulation were only assessed for protein 
antigens CP0529, CP0177-1, CP0020-1 and CP0504.  The results obtained 10 
days post 2nd and 10 days post 3rd immunizations are shown in figure 10 A and 
B. Interestingly candidate CP0529 showed the strongest response of all 
selected antigens in terms of IL-4 production, but only when administered 
without the adjuvant IC31®, indicating the induction of a strong TH2-type 
response to this antigen, which is further supported by the low levels of IFN-γ 
production in response to CP0529. Regarding the adjuvantive effect of IC31® 
on IL-4 production, CP0177-1 was the only antigen showing an increased IL-4 
response comparing groups immunized with and without adjuvant. 
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Figure 11: IL-4 ELIspot; CP0529, CP0177-1, CP0020-1, CP0504 post 3rd immunization. Mice 
were immunized 3 times i.p. in a distance of each 14 days. 10 days post 3rd immunization 3 
mice per group were sacrificed and IL-4 secretion by splenic lymphocytes in response to ex 
vivo restimulation was assessed. Mean ± SD. SFC (spot forming cells). 
 
While candidates CP0504 and CP0020-1 showed an elevated IL-4 response in 
groups immunized with adjuvant after 2 immunizations, this effect was not 
observed post 3rd immunization, where IL-4 levels in each both experimental 
groups showed equal responses. 
Together these results strongly support the dominating TH1 driving 
activity in the mixed TH1/TH2 adjuvantive effect of IC31®, as well as the 
effectivity in eliciting a systemic immune response by this adjuvant either 
when administered intra nasally or intra peritoneal. 
 
4.2.3 Antigen-dependent induction of CD154 expression 
 
As mentioned in the beginning, interaction between CD154 and CD40 on 
APCs is a fundamental process in the generation of an effective antigen 
specific adaptive immune response through the activation and induction of 
proliferation of DCs, B cells and macrophages. In order to measure the 
specifically induced upregulation of CD154 cell marker expression by CD4+ T 
cells by antigen restimulation following intra nasal immunization, flow 
cytometric analysis was conducted. The procedures of cell preparation, CD154 
and CD4 specific staining as well as ex vivo restimulation are described in 
sections 6.10, 6.15 and 6.16, materials and methods.  
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Figure 12: CD154 FCM 10 days post 3rd i.n. immunization from A: splenic lymphocytes;  
B: lung-derived lymphocytes: Total spleen cells/lung cells were restimulated ex vivo for 6 
hours with 10 µg/ml of antigen prior to acquisition. Different experimental groups and stimuli 
are indicated on top of each dot blot. Events shown were gated from FCS/SSC (lymphocytes) 
and the CD4+ T cell population (FITC). The percentages of CD4/CD154 double positive T 
cells in the CD4+ T cell population are shown on the bottom of each dot blot. 
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CD4+ T cells derived from spleens and lungs, representative for systemic and 
local induction of basic mechanisms in adaptive immune responses 
respectively, were analyzed from intra nasally immunized BALB/c mice. 
Figure 11A shows the results from CD154 FCM analysis of splenic 
CD4+ T cells; figure 11B the results of lung-derived CD4+ T cells for the 
candidate antigens CP0529 and CP0177-1.  
Upregulation of CD154 on splenic CD4+ T cells following 
restimulation was neither observed for CP0529 nor CP0177-1 in groups 
immunized with the respective antigen. Immunization with CP0177-1 in 
combination with IC31® in contrast led to a slight increase of CD154 
expression following restimulation when compared to the respective medium 
controls: 1.31 fold for CP0177-1, indicating a systemic response to CP0177-1 
following intra nasal immunization in combination with IC31®. 
In respect to the upregulation of CD154 at local compartments a 
different picture was obtained. Again no elevated CD154 response were seen in 
groups immunized with the antigen (CP0529, CP0177-1) alone, but a 
significant increase of CD154 expression was observed in groups immunized 
in combination with the adjuvant IC31® for both antigens. CP0529 induced 
upregulation of CD154 was 2.90 fold, while the increase in CD154 expression 
induced by restimulation with CP0177-1 was 5.76 fold in comparison to the 
medium control.  
 Figure 13A and B show the antigen specific upregulation of CD154 by 
candidates CP0020-1 and CP0504. Interestingly ex vivo restimulation with 
CP0020-1 led to a substantial increase in CD154 expression in both CD4+ T 
cells derived from murine spleens and lungs. Additionally, upregulation of 
CD154 expression was observed in groups immunized either with the antigen 
alone or in combination with IC31®: spleen with IC31®: 1.91 fold; spleen with-
out IC31® 2.14 fold; lung with IC31®: 5.88 fold; lung without IC31®: 2.80 fold 
(corresponding to the respective medium control). 
 Notable upregulation of CD154 in response to CP0504 was only 
observed in groups immunized with the antigen in combination with IC31®. 
The increase was 4.79 fold respective to the medium control. Though slight 
CD154 upregulation was also observed in other groups: spleen with IC31®: 
1.22 fold; spleen with-out IC31®: 1.35 fold; lung without IC31®: 1.43 fold. 
 Regarding the recombinant Chlamydia proteins CP0879 and CP0409, 
antigen induced CD154 upregulation on CD4+ T cells was only assessed post 
2nd intra nasal immunization (figure 14A and B). Restimulation with CP0879 
showed a considerable increase of CD4/CD154 double-positive cells in spleens 
(1.80 fold) and lungs (1.95 fold) of those groups immunized with adjuvanted 
protein, whereas groups immunized without IC31® showed a smaller increase  
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Figure 13: CD154 FCM 10 days post 3rd i.n. immunization from A: splenic lymphocytes;  
B: lung-derived lymphocytes: Total spleen cells/lung cells were restimulated ex vivo for 6 
hours with 10 µg/ml of antigen prior to acquisition. Different experimental groups and stimuli 
are indicated on top of each dot blot. Events shown were gated from FCS/SSC (lymphocytes) 
and the CD4+ T cell population (FITC). The percentages of CD4/CD154 double positive T 
cells in the CD4+ T cell population are shown on the bottom of each dot blot. 
 - 26 -    
A 
 
B 
Figure 14: CD154 FCM 10 days post 3rd i.n. immunization from A: splenic lymphocytes;  
B: lung-derived lymphocytes: Total spleen cells/lung cells were restimulated ex vivo for 6 
hours with 10 µg/ml of antigen prior to acquisition. Different experimental groups and stimuli 
are indicated on top of each dot blot. Events shown were gated from FCS/SSC (lymphocytes) 
and the CD4+ T cell population (FITC). The percentages of CD4/CD154 double positive T 
cells in the CD4+ T cell population are shown on the bottom of each dot blot. 
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in terms of CD154 upregulation on CD4+ T cells: spleen without IC31®: 1.53 
fold; lung without IC31®: 1.39 fold.  
 CP0409 restimulation showed positive responses in terms of CD154 
upregulation in all tested groups. Though, the differences between groups 
immunized without adjuvant compared to those which received antigen and 
adjuvant were less pronounced: spleen with IC31®: 1.78 fold; spleen with-out 
IC31® 1.62 fold; lung with IC31®: 1.35 fold; lung without IC31®: 1.26 fold. 
Table 2 summarizes the results obtained from CD154 flow cytometric 
analysis experiments. 
 
 
Organ 
 
Immunization 
 
CP0529 
 
CP0177-1 
 
CP0020-1 
 
CP0504 
 
CP0879 
 
CP0409 
Antigen + 
IC31® 
- 1.31 1.91 1.22 1.80 1.78 
Spleen 
Antigen - - 2.14 1.35 1.53 1.62 
Antigen + 
IC31® 
2.90 5.76 5.88 4.79 1.95 1.35 
Lung 
Antigen 1.12 - 2.80 1.43 1.39 1.26 
 
Table 2: Summary: Antigen induced upregulation of CD154 on CD4+ T cells following intra 
nasal immunization and ex vivo restimulation (3 immunizations: CP0529, CP0177-1, CP0020-
1, CP0504; 2 immunizations: CP0879, CP0409); numbers are shown as x-fold increase of % of 
CD4/CD154 double-positive cells in comparison to the respective medium control. 
 
4.2.4 Antigen-specific immunoglobulin responses 
 
Antigenicity of selected Chlamydia pneumoniae candidate proteins was 
assessed by Enyme-linked Immunosorbent Assay (ELISA) using sera obtained 
from mice that were immunized intra nasally or intra peritoneal. The applied 
methods are described in section 6.14, materials and methods.  
In order to obtain a comprehensive picture of antigen induced 
immunoglobulin production both, total serum IgG titers as well as serum IgA 
titers were assessed. Prior to the assessment of immunoglobulin titers by 
ELISA each recombinant protein was titrated using serum from mice 
immunized with the relevant antigen, serum from mice immunized with an 
irrelevant antigen as well as sera from naïve mice as controls. The optimal 
coating concentration was defined as the concentration of recombinant protein 
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which allowed the best differentiation between sera of mice immunized with 
the relevant antigen in comparison to sera from control groups (not shown).  
The results obtained from ELISA for candidate antigens CP0529, CP0177-1, 
CP0020-1 and CP0504 respectively, are shown in figure 15A-D. 
 
A 
B 
C 
 
 
 
D 
Figure 15: A: CP0529; B: CP0177-1; C: CP0020-1; D: CP0504; ELISA of serum from 
BALB/c mice obtained 10 days post 3rd intra nasal/intra peritoneal immunization. Total serum 
IgG titers are shown on the left, serum IgA titers on the right. Pooled serum samples of each 3 
mice were used and serially diluted as shown along the X-axis. The results were expressed as 
OD405nm*1000 values as shown along the Y-axis. Each curve is shown as nonlinear regression 
over background subtracted individual values. 
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As can be seen in figure 15A, i.p. immunizations with candidate CP0529 
elicited strong IgG responses, while antibody titers where higher in the group 
immunized with IC31® as an adjuvant. As well as i.p. immunization, i.n. 
immunizations induced antigen specific IgG production in both groups, but at a 
lower level. No IgA response was detected in any group of mice immunized 
with CP0529.  
CP0177-1 specific IgG antibodies where detected at the highest level in the 
group immunized i.p. in combination with IC31®, followed by the group of 
mice immunized i.p. with the antigen alone and followed by the experimental 
group which had received CP0177-1 plus IC31® intra nasally. Low levels of 
IgG where furthermore detected in mice immunized i.n. with CP0177-1 alone. 
CP0177-1 specific serum IgA was found in groups immunized i.n. with 
adjuvanted antigen and at lower but similar levels in groups immunized either 
with CP0177-1 alone or in combination with IC31® via the i.p. route. 
Candidate CP0020-1 clearly showed the overall highest IgG titers 
indicating high antigenicity of this protein in both routes of immunization 
while the adjuvant IC31® additionally showed an enhancing effect.  
 
Fehler!A 
 
B 
Figure 26: A: CP0879; B: CP0409; ELISA of serum from BALB/c mice obtained 10 days post 
3rd intra nasal and 10 days post 2nd intra peritoneal immunization. Total serum IgG titers are 
shown on the left, serum IgA titers on the right. Pooled serum samples of each 3 mice were 
used and serially diluted as shown along the X-axis. The results were expressed as 
OD405nm*1000 values as shown along the Y-axis. Each curve is shown as nonlinear regression 
over background subtracted individual values. 
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Furthermore, potent IgA induction was observed in groups that had received 
CP0020-1 i.n. while low IgA titers could be detected in i.p. immunized groups. 
Interestingly intra nasal immunization with CP0020-1 alone showed a stronger 
serum IgA induction than immunization with IC31®-adjuvanted protein, while 
in contrast serum IgA levels where higher in the i.p. immunized that also 
received the adjuvant than in the group which was immunized with CP0020-1 
alone.  
 In the case of CP0504, antigen specific reaction by IgG antibodies was 
detected in i.p. immunized groups showing higher immunoglobulin titers in 
mice immunized with antigen and adjuvant. Low CP0504 specific serum IgG 
titers where furthermore seen in mice immunized i.n. with CP0504 protein 
alone, but not in the group where IC31® was included. Furthermore no antigen 
specific serum IgA was induced neither by i.p. immunization nor i.n. 
immunization. 
Figures 16A and B show the results for candidate antigens CP0879 and 
CP0409 respectively. ELISA from sera of BALB/c mice immunized 2 times 
i.p. with CP0879 alone showed a specific IgG response in contrast to the group 
immunized with adjuvanted protein. IgA response to CP0879 after 2 i.p. 
injections was absent. Intra nasal immunization, gave rise to both IgG and IgA 
responses, where IgG responses where stronger in the group immunized with 
the antigen alone.  
 Regarding the induction of humoral response in the case of CP0409, 
only sera obtained from intra nasally immunized mice contained antigen 
specific IgG and IgA. Similar to the case of CP0879 IgG responses where 
higher in the groups immunized with the protein alone whereas serum IgA 
titers were higher in the group immunized with adjuvanted protein.   
 
4.3 Cpn K6 infection-primed immune responses 
 
Two different mouse strains, BALB/c and C57BL/6, were used here in order to 
assess T cell responses and humoral immunogenicity to the selected Cpn 
candidate antigens by infection-primed immune responses. The results should 
give an idea about the recognition of these antigens during a simulated, natural  
C. pneumoniae infection in mice, as the AIP® technology only gives 
information about the antigenicity of these candidates during Cpn infection in 
humans.  
It should be noted here, that BALB/c (H2d) mice have been reported to 
preferentially develop a TH2-type immune response and to be more susceptible 
to Cpn infection/intracellular pathogens in general, which stands in contrast to 
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observations made with C57BL/6 (H2b). The reason for these observations may 
be due to the greater CD4+CD25+ regulatory T cell population of BALB/c 
mice, as found in a Leishmania major infection model [89]. 
  T cell responses were assessed from spleen cells derived from 
infected/reinfected mice by cultured IFN-γ ELIspot, where infection primed T 
cells specifically reacting to an antigen by IFN-γ secretion, were expanded in 
vitro over a period of 48 hours followed by the standard procedure of IFN-γ 
ELIspot.  
Humoral responses induced by C. pneumoniae infection were assessed 
by ELISA using sera from infected/reinfected animals. The applied methods 
are described in section 6.7, 6.11, 6.12 and 6.14, materials and methods. 
Figures 17 and 18 respectively show infection-primed T cell responses, which 
were obtained by cultured IFN-γ ELIspots, against the selected Cpn antigens in 
BALB/c and C57BL/6 mice.  
 IFN-γ responses of spleen cells that were derived from infected/ 
reinfected BALB/c mice clearly showed that 5 out of the 6 selected Cpn 
antigens were recognized by T cells, inducing IFN-γ production, during 
infection. These antigens were: CP0529, CP0177-1, CP0020-1, CP0504 and 
CP0409.  
 
 
Figure 17: Cultured IFN-γ ELIspot from spleen cells derived 12 days post reinfection from 
Cpn K6 infection primed BALB/c mice: Total spleen cells of each experimental group 
(indicated along the X-axis) where cultured ex vivo for 48 hours in presence of 5 µg/ml of the 
respective Cpn antigen. Subsequent cells were transferred onto ELIspot plates and restimulated 
for 24 hours with 2 µg/ml of the respective Cpn antigen. Mean ± SD. SFC (Spot Forming 
Cells).  
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Figure 18:  Cultured IFN-γ ELIspot from spleen cells derived 12 days post reinfection from 
Cpn K6 infection primed C57BL6/c mice: Total spleen cells of each experimental group 
(indicated along the X-axis) where cultured ex vivo for 48 hours in presence of 5 µg/ml of the 
respective Cpn antigen. Subsequent cells were transferred onto ELIspot plates and restimulated 
for 24 hours with 2 µg/ml of the respective Cpn antigen. Mean ± SD. SFC (Spot Forming 
Cells). 
 
In contrast, the results obtained from C57BL/6 mice indicated that 3 out 
of 6 candidates were recognized by this mouse strain during Cpn infection, 
when compared to the responses of the naïve control group. In this case the 
proteins which were recognized are CP0504, CP0177-1 and CP0020-1, 
indicating the predominant induction of a TH2-type response to Cpn antigens 
CP0529 and CP0409 during Cpn infection. 
As mentioned in the beginning of this section, infection primed humoral 
responses were assessed by ELISA. This experiment resembled a repetition of 
the results obtained from the screening during the AIP®, but in mice. The 
results are shown in figures 19A-C (C0529, CP0177-1, CP0020-1 respectively) 
and figures 20D-F (CP0504, CP0879, CP0409 respectively).  
As in immunization studies, also here, antigen specific total serum IgG 
and IgA titers were assessed. In general, Cpn K6 infection elicited specific IgG 
antibody responses to all selected candidate antigens in BALB/c and C57BL/6 
mice, while the later mouse strain clearly showed the lower titers. 
Infection-primed serum IgA responses were detected for candidates 
CP0177-1, CP0020-1, CP0504, CP0879 and CP0409, while IgA antibodies 
against candidates CP0504 and CP0879 were only induced in C57BL/6 mice. 
Candidate CP0020-1, as already observed in immunization studies, was 
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predominantly recognized in terms of total serum IgG and serum IgA antibody 
titers in both BALB/c and C57BL/6 mice.  
Furthermore, variations regarding the different mouse strains, except 
the overall lower antigen specific IgG titers in C57BL/6 mice compared to 
BALB/c mice, were especially seen in serum IgA responses.  
 
 
Fehler!
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Figure 19: A: CP0529; B: CP0177-1; C: CP0020-1; ELISA of serum from BALB/c and 
C57BL/6 mice obtained 12 days post intra nasal reinfection with Cpn K6. Total serum IgG 
titers are shown on the left, serum IgA titers on the right. Pooled serum samples of each 5 mice 
were used and serially diluted as shown along the X-axis. The results were expressed as 
OD405nm*1000 values as shown along the Y-axis. Each curve is shown as nonlinear regression 
over background subtracted individual values. 
  
Here the majority of antigens (CP0177-1, CP0504, CP0879 and CP0409) led to 
the generation of higher serum IgA titers in C57BL/6 mice. The exceptions 
were CP0529 (which did not elicit any IgA response during Cpn infection) and 
CP0020-1 which elicited higher serum IgA titers in BALB/c mice than in 
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C57BL/6 mice. However, Cpn infection-induced anti-CP0020-1 serum IgA 
antibody titers surpassed all detected serum IgA titers generated against the 
other candidate proteins. 
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Figure 20: A: CP0504; B: CP0879; C: CP0409; ELISA of serum from BALB/c and C57BL/6 
mice obtained 12 days post intra nasal reinfection with Cpn K6. Total serum IgG titers are 
shown on the left, serum IgA titers on the right. Pooled serum samples of each 5 mice were 
used and serially diluted as shown along the X-axis. The results were expressed as 
OD405nm*1000 values as shown along the Y-axis. Each curve is shown as nonlinear regression 
over background subtracted individual values. 
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4.4 Chlamydia pneumoniae K6 challenge studies 
 
As a central part of this study, dealing with potential subunit-vaccine candidate 
proteins, immunization-induced protection against C. pneumoniae infection 
was assessed in a BALB/c mouse model. The “gold-standard” for the 
estimation of reduction of bacterial loads in murine lungs, is the evaluation of 
Inclusion Forming Units (IFU) by in vitro infection of HEp-2 cells with 
different dilutions of lung homogenates derived from challenged animals, 
followed by immunofluorescent staining of the formed chlamydial inclusions. 
Sections 6.6, 6.7 and 6.9, material and methods, give a more detailed 
description of the applied techniques for the evaluation of protection.  
 BALB/c mice where sacrificed 10 days post intra nasal infection with 
each 1*106 IFUs of Cpn K6 strain. Each mouse had received 3 intra nasal 
vaccinations with the respective recombinant Cpn antigen (40 µg/mouse/dose) 
either in combination with IC31® or without adjuvant, prior to intra nasal 
bacterial challenge. The experimental groups consisted of each 5 female 
BALB/c mice, and were kept under specified-pathogen-free (SPF) conditions 
prior to infection with Cpn K6 and group wise, in separated and ventilated 
cages, post infection. Figures 21, 22 and 23 show the results of immunization-
challenge studies including the antigens CP0529 and CP0177-1, CP0020-1 and 
CP0504, CP0879 and CP0409 respectively.  
Immunizations with candidate CP0529, either in combination with 
IC31® and when administered without adjuvant, led to significant decreases of 
bacterial loads in murine lungs following 3 intra nasal vaccinations. Keeping 
the previous results from immunization studies in mind, the mechanism of 
reduction of bacterial loads by immunization with CP0529 seemed to be the 
result of a strong but not fully protective TH2-type immune response to this 
antigen.  
Regarding the antigen CP0177-1 a strong protective effect was 
observed in the group immunized in combination with IC31®, as can be seen in 
the highly reduced number of IFUs. Unsurprisingly this effect was not 
observed in the group immunized with CP0177-1 alone, as immunization 
primed immune responses did only lead to high levels of IFN-γ secreting T 
cells as well as CD154 induction on CD4+ T cells in mice immunized with 
IC31®-adjuvanted  CP0177-1.  
Interestingly CopN and MOMP adjuvanted with IC31® led to a 
substantial reduction of IFUs, which is consistent with previous studies dealing 
with these two antigens (see introduction), and supporting the dominating TH1-
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driving adjuvantive effect of IC31® that potentially induces the establishment 
of a protective immune response against infection with Cpn. 
 
 
Figure 21: CP0529, CP0177-1: Assessment of IFUs 10 days post i.n. challenge: BALB/c mice 
were infected i.n. with each 1*106 IFUs 10 days following 3rd i.n. vaccination with each 40 µg 
of antigen per mouse including or not including IC31® as an adjuvant. As control groups 
served mice immunized 3 times intra nasally with IC31®-adjuvanted CopN as well as MOMP, 
MOMP adjuvanted with CT and naïve mice as infection control. * = p < 0.05; ** = p < 0.01 
(Mann-Whitney-U-Test).  
 
Candidate CP0020-1 already showed a potent induction of TH2-type 
responses during immunization studies. However, in contrast to CP0529, i.n. 
immunization with CP0020-1 (with and without IC31®) resulted in intense T 
cell responses, including the secretion of the type I cytokine IFN-γ.  
Regarding reduction of bacterial loads, a substantial effect was seen in 
those groups of mice that had received CP0020-1. CP0020-1 was also included 
in the 3rd round of immunization-challenge studies (figure 23). In contrast to 
the 2nd (figure 21) round, here the reduction of IFUs was stronger in the group 
immunized in combination with the adjuvant IC31®. Though, differences 
between these experimental groups were not significant.  
Reduction of IFUs in the case of immunizations with CP0504, showed 
a significant effect in combination with IC31® and a minor, insignificant effect 
with the protein alone. This might be due to the fact that CP0504 was not able 
to elicit neither serum IgG nor IgA responses when it was administered intra 
nasally, even when combined with IC31®.  
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Figure 22: CP0020-1, CP0504: Assessment of IFUs 10 days post i.n. challenge: BALB/c mice 
were infected i.n. with each 1*106 IFUs 10 days following 3rd i.n. vaccination with each 40 µg 
of antigen per mouse including or not including IC31® as an adjuvant. As control groups 
served mice immunized 3 times intra nasally with IC31®-adjuvanted CopN as well as MOMP, 
MOMP adjuvanted with CT and naïve mice as infection control. * = p < 0.05; ** = p < 0.01 
(Mann-Whitney-U-Test). 
 
Furthermore, T cell responses in terms of IFN-γ secretion and CD154 
upregulation where only strong when CP0504 was delivered in combination 
with IC31®. 
Finally, neither of the two antigens CP0879 and CP0409 showed a 
significant reduction of bacterial loads following 3 intra nasal immunizations 
even not, when immunizations where performed with adjuvanted recombinant 
protein.  In the case of CP0409, this result was not surprising, given the low 
immunogenicity of this antigen.  
CP0879 in contrast, showed good immunogenicity, especially in 
combination with the adjuvant IC31®, but as infection-primed immune 
response studies showed, CP0879 might not be at all, or only in low levels, 
accessible to T cells of the immune system of the host, which could explain the 
obtained results in immunization–challenge studies for this recombinant Cpn 
antigen. 
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Figure 23: CP0020-1, CP0879, CP0409: Assessment of IFUs 10 days post i.n. challenge: 
BALB/c mice were infected i.n. with each 1*106 IFUs 10 days following 3rd i.n. vaccination 
with each 40 µg of antigen per mouse including or not including IC31® as an adjuvant. As 
control groups served mice immunized 3 times intra nasally with IC31®-adjuvanted CopN, 
IC31® alone and naïve mice as infection control. * = p < 0.05; ** = p < 0.01 (Mann-Whitney-
U-Test). 
 
Importantly, intra nasal immunizations with the adjuvant IC31® alone 
did not show to have a significant effect in reducing bacterial burdens or in 
deteriorating infection in the lungs of C. pneumoniae-challenged mice. 
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4.5 Characterization of T cell responses using peptide libraries 
 
Based on immunogenicity and efficacy data the two top protective antigens, 
CP0177-1 and CP0020-1, were selected in order to further characterize T cell 
responses using peptide libraries consisting of 15-mers, overlapping by 10 
residues and spanning the entire sequence of these recombinant proteins. For 
CP0177-1 a peptide library of 76 15-mers was generated covering the 382 
residues. In the case of CP0020-1, which consists of 466 residues, 86 15-mers 
were generated. Peptides of the respective recombinant proteins were 
denominated according to their position inside the synthesis plate (A1, A2, 
A3…A12, B1…) until the last position. 
 As the first part of T cell response characterization and epitope 
mapping, the entire peptide libraries were used for ex vivo restimulation of 
spleen cells derived from immunized BALB/c mice. Immunizations were 
performed s.c. and i.d., at the tail base with 100 µl of vaccine per injection, 
either with a total of 40 µg recombinant protein alone or in combination with 
IC31® (100/4) as an adjuvant.  
In addition, peptide specific induction of lymphocyte proliferation was 
assessed by flow cytometric analysis using carboxyfluorescein diacetate 
succinimidyl ester (CFSE) combined with selective staining of  CD3+ T cells 
and CD4+ T cells. The application of this method enabled the differentiation 
between proliferating CD3+ T cell- and CD4+ T cell populations, thereby 
providing particularized information about the responding T cell sub-
population.  
 The second part of T cell response characterization involved peptide 
library screening using spleen cells derived from Cpn K6 infected/reinfected 
BALB/c and C57BL/6 mice, giving information about epitopes to which 
infection primed T cells of the respective mouse strain react. Naïve mice 
served as control groups in all screening experiments. Each experimental group 
consisted of 5 female mice. 
 
4.5.1 Characterization of T cell responses using the CP0177-1 peptide 
library 
 
The results of CP0177-1 T cell epitope mapping by IFN-γ ELIspot of spleen 
cells derived from s.c. + i.d. immunized animals are shown in figure 24A-C. 
No protruding signal was obtained in this screening round, though 
restimulation with 10 µg/ml of the whole protein resulted in 120 IFN-γ 
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SFC/0.5*106 in the group immunized with the adjuvanted antigen and 45 IFN-γ 
SFC/0.5*106 in the group immunized with CP0177-1 alone (not shown). 
 
 
A 
 
B 
 
C 
Figure 24: IFN-γ ELIspot 10 days post 3rd immunization: CP0177-1 peptide library screening 
using spleen cells derived from BALB/c mice immunized 3 times s.c. and i.d. with A: 40 µg 
CP0177-1 + IC31® (100/4); B: 40 µg CP0177-1; C: naïve control group; in a distance of 14 
days. Ex vivo restimulation was conducted with 5 µg/ml of the respective 15-mer as shown 
along the X-axis. Concentrations of irrelevant antigens were 10 µg/ml for CopN and 2 µg/ml 
for peptide B8.1 (CopN). Mean ± SD. SFC (Spot Forming Cells). 
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Figure 25: IFN-γ ELIspot 12 days post reinfection: CP0177-1 peptide library screening using 
spleen cells derived from infected/reinfected BALB/c mice; A: infected/reinfected BALB/c B: 
naïve control group; Ex vivo restimulation was conducted with 5 µg/ml of the respective 15-
mer, as shown along the X-axis. Concentrations of irrelevant antigens were 10 µg/ml for 
BAP038 and 5 µg/ml for peptide 19. Mean ± SD. SFC (Spot Forming Cells). 
 
However, a cluster of IFN-γ responses, ranging from 15-mer D1 to D6 
was observed in both groups, indicating the presence of stimulatory properties 
in terms of IFN-γ secretion inside this cluster. Elevated IFN-γ levels in 
response to these peptides were additionally observed in spleen cells derived 
from Cpn K6 infected BALB/c but not C57BL/6 mice (figures 25 and 26).   
In dissent, stimulatory characteristics for these 15-mers were not seen in 
proliferation assays with the only exception of peptide D1 (SILNFLKNPAVQ 
QKM), which also showed the strongest IFN-γ response in ELIspots with 
spleen cells derived from infected/reinfected BALB/c mice (figure 25A and 
28A). 
In CFSE-CD3+-CD4+ FCM analysis, further induction of proliferation 
was only observed in groups restimulated with the whole protein CP0177-1 
and in response to restimulation with peptides G2 (GATVVPNVNVNLGGI) 
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or G3 (PNVNVNLGGILEHHH) (figures 27 and 28). Though, neither of the 
peptides led to significant increases in IFN-γ secretion following ex vivo 
restimulation of spleen cells derived from immunized animals. 
Interestingly, restimulation of spleen cells, derived from mice 
immunized with adjuvanted CP0177-1, with 10 µg/ml of the whole protein 
induced strong proliferation, not only in the CD4+ T cell population, but also in 
a CD3+ T cell population that was not CD4+, leaving CD8+ T cells as 
candidates. However, this response was not observed in the experimental group 
immunized with the antigen alone, where mainly CD4+ T cells responded by 
proliferation upon restimulation and proliferative responses observed in the 
CD3+ T cell population of the naïve group surpassed the ones seen in the group 
immunized with CP0177-1 alone (figure 27 A).  
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B 
Figure 26: IFN-γ ELIspot 12days post reinfection: CP0177-1 peptide library screening using 
spleen cells derived from infected/reinfected C57BL/6 mice; A: infected/reinfected C57BL/6 
B: naïve control group; Ex vivo restimulation was conducted with 5 µg/ml of the respective 15-
mer, as shown along the X-axis. Concentrations of irrelevant antigens were 10 µg/ml for 
BAP038 and 5 µg/ml for peptide 19. Mean ± SD. SFC (Spot Forming Cells). 
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Figure 27: CFSE-CD3+-CD4+ differential proliferation screening. Spleen cells of CP0177-1 
s.c. + i.d. immunized BALB/c mice 10 days post 3rd immunization: A: Restimulation with 10 
µg/ml CP0177-1; B: Restimulation with 10 µg/ml irrelevant Peptide B8.1 (CopN); C: 
Restimulation with TCM; Experimental groups are indicated on the right. Histograms are 
shown from FSC/SSC gated lymphocytes, APC gated CD3+ T cells and PE-Cy7 gated CD4+ T 
cells as indicated on the top of each row. Percent of proliferating cells of the respective 
lymphocyte population are shown in the upper left quadrant of each histogram.   
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Figure 28: CFSE-CD3+-CD4+ differential proliferation screening. Spleen cells of CP0177-1 
s.c. + i.d. immunized BALB/c mice 10 days post 3rd immunization: A: Restimulation with 10 
µg/ml D1 (SILNFLKNPAVQQKM) B: Restimulation with 10 µg/ml G2 (GATVVPNVNVNL 
GGI); C: Restimulation with 10 µg/ml G3 (PNVNVNLGGILEHHH); Experimental groups are 
indicated on the right. Histograms are shown from FSC/SSC gated lymphocytes, APC gated 
CD3+ T cells and PE-Cy7 gated CD4+ T cells as indicated on the top of each row. Percent of 
proliferating cells of the respective lymphocyte population are shown in the upper left quadrant 
of each histogram.   
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4.5.2 Characterization of T cell responses using the CP0020-1 peptide 
library 
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Figure 29: IFN-γ ELIspot 10 days post 3rd immunization: CP0020-1 peptide library screening 
using spleen cells derived from BALB/c mice immunized 3 times s.c. and i.d. with A: 40 µg 
CP0020-1 + IC31® (100/4); B: 40 µg CP0020-1; C: naïve control group; in a distance of 14 
days. Ex vivo restimulation was conducted with 5 µg/ml of the respective 15-mer as shown 
along the X-axis. Concentrations of irrelevant antigens were 10 µg/ml for CopN and 2 µg/ml 
for peptide B8.1 (CopN). Mean ± SD. SFC (Spot Forming Cells). 
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In contrast to CP0177-1, CP0020-1 peptide library screening led to more 
distinguished results. As IFN-γ ELIspots from immunized BALB/c mice 
showed, five peptides namely A11, B1, C9, D9 and D10 stimulated a 
significant increase in IFN-γ secretion compared to the respective control 
(figure 29A-C). Though, positive stimulation was only observed in the 
experimental group immunized with adjuvanted CP0020-1, with the exception 
of peptide A11 which also showed to elicit elevated IFN-γ secretion in the 
group immunized with CP0020-1 alone.  
Responses in IFN-γ ELIspot to restimulation with 10 µg/ml of the 
whole protein where 200 SFC/0.5*106 and 91 SFC/0.5*106 in the group 
immunized with IC31® as an adjuvant and the group which received CP0020-1 
alone respectively (not shown). 
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Figure 30: IFN-γ ELIspot 12 days post reinfection: CP0020-1 peptide library screening using 
spleen cells derived from infected/reinfected BALB/c mice; A: infected/reinfected BALB/c B: 
naïve control group; Ex vivo restimulation was conducted with 5 µg/ml of the respective 15-
mer, as shown along the X-axis. Concentrations of irrelevant antigens were 10 µg/ml for 
BAP038 and 5 µg/ml for peptide 19. Mean ± SD. SFC (Spot Forming Cells). 
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Interestingly, peptides D9 and D10 also showed to be the strongest peptides 
stimulating IFN-γ secretion in ELIspots, using spleen cells from Cpn K6 
infected/reinfected BALB/c mice, indicating that these peptides were also 
recognized during C. pneumoniae infection. In dissent, IFN-γ ELIspots of 
spleen cells from infected/reinfected C57BL/6 mice showed to respond in 
highest levels to restimulation with peptides D3 (LAGKYGNQATLTQTF) and 
D4 (GNQATLTQ TFADGRV). 
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Figure 31: IFN-γ ELIspot 12 days post reinfection: CP0020-1 peptide library screening using 
spleen cells derived from infected/reinfected C57BL/6 mice; A: infected/reinfected C57BL/6 
B: naïve control group; Ex vivo restimulation was conducted with 5 µg/ml of the respective 15-
mer, as shown along the X-axis. Concentrations of irrelevant antigens were 10 µg/ml for 
BAP038 and 5 µg/ml for peptide 19. Mean ± SD. SFC (Spot Forming Cells). 
 
Regarding the induction of lymphocyte proliferation upon ex vivo 
restimulation, FCM analysis showed that especially peptides A11, D9 and D10 
elicited cellular responses (figure 33A-C). Primarily CD4+ T cells were found 
to react by proliferation in response to restimulation with these peptides, 
whereas peptide D10 clearly showed the strongest inductive potential.  
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Figure 32: CFSE-CD3+-CD4+ differential proliferation screening. Spleen cells of CP0020-1 
s.c. + i.d. immunized BALB/c mice 10 days post 3rd immunization: A: Restimulation with 10 
µg/ml CP0020-1 B: Restimulation with 10 µg/ml irrelevant peptide B8.1 (CopN); C: 
Restimulation with TCM. Experimental groups are indicated on the right. Histograms are 
shown from FSC/SSC gated lymphocytes, APC gated CD3+ T cells and PE-Cy7 gated CD4+ T 
cells as indicated on the top of each row. Percent of proliferating cells of the respective 
lymphocyte population are shown in the upper left quadrant of each histogram.   
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Figure 33: CFSE-CD3+-CD4+ differential proliferation screening. Spleen cells of CP0020-1 
s.c. + i.d. immunized BALB/c mice 10 days post 3rd immunization: A: Restimulation with 10 
µg/ml A11 (LHKYEVERATVAKSI); B: Restimulation with 10 µg/ml D9 (QGVLTPEQFTIF 
AEI); C: Restimulation with 10 µg/ml D10 (PEQFTIFAEIATELQ). Experimental groups are 
indicated on the right. Histograms are shown from FSC/SSC gated lymphocytes, APC gated 
CD3+ T cells and PE-Cy7 gated CD4+ T cells as indicated on the top of each row. Percent of 
proliferating cells of the respective lymphocyte population are shown in the upper left quadrant 
of each histogram.   
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Additionally peptides A12, B1, G3, G8 and G9  elicited proliferative responses 
(not shown), while B1 and G3 where also found to give positive signals in 
IFN-γ ELIspot from immunized animals and G9 in IFN-γ ELIspot from 
infected /reinfected BALB/c mice, but not vice versa. 
 Restimulation with the whole protein CP0020-1 in proliferation 
experiments resulted in proliferative responses in the CD4+ T cell population as 
well as in a CD3+ CD4- T cell population. This induction of most probably 
CD8+ T cells, was not only observed in the group immunized with CP0020-1 
adjuvanted by IC31® but also in the group that was immunized with the 
recombinant antigen alone (figure 32A-C). 
 
4.6 Immunofluorescence microscopy  
 
With the purpose to localize the selected Cpn antigens, sera from immunized 
BALB/c mice were used for the detection of proteins in Cpn K6 infected HEp-
2 cells using fluorochrome-labeled anti-mouse antibodies. Supplementary, anti-
Cp0585 antibodies were used for the visualization if the inclusion membrane, 
as protein Cp0585 is a well characterized antigen present in the inclusion of 
Cpn.   
 As shown in figure 34A and B anti-CP0529 sera reacted with Cpn RBs 
at 44 hours post infection. No reaction of anti-CP0529 sera was observed with 
Cpn EBs at this time point.  
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Figure 34: CP0529 Immunofluorescence; A: HEp-2 cells 44 hours post infection; AI: anti-
Cp0585; AII: DAPI; AIII: anti-CP0529 serum; AIV: overlay; B: HEp-2 cells 44 hours post 
infection; BI: anti-Cp0585; BII: anti-CP0529 serum; BIII: DAPI; BIV: overlay; 3*105 HEp-2 
cells were plated on 13 mm diameter glass slides in 24-well plates and incubated for 20 hours 
before infection with Cpn K6 at a MOI of 2. Subsequently HEp-2 cells were incubated for 44 
hours followed by immunofluorescent staining of the inclusion membrane, the respective 
antigen and DNA staining with DAPI. Sera were derived from mice immunized 3 times with 
CP0529 40 µg/mouse + IC31® and collected by terminal bleeding 10 days post 3rd i.p. 
immunization.  
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The respective control is shown in figure 40A, where unspecific reactivity and 
a tendency of these antibodies to oligomerization were observed. 
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Figure 35: CP0177-1 Immunofluorescence; A: HEp-2 cells 1 hour post infection; AI: anti-
Cp0585 (white); AII: anti-CP0177-1 serum; AIII: DAPI; A-IV: overlay; B: HEp-2 cells 1 hour 
post infection; BI: anti-Cp0585; BII: anti-CP0177-1 serum; BIII: DAPI; BIV: overlay; 
1.5*105 HEp-2 cells were plated on 13 mm diameter glass slides in 24-well plates and 
incubated for 21 hours before infection with Cpn K6 at a MOI of 2. Subsequently HEp-2 cells 
were incubated for 1 hour followed by immunofluorescent staining of the inclusion membrane, 
the respective antigen and DNA staining with DAPI. Sera were derived from mice immunized 
3 times with CP0177-1 40 µg/mouse + IC31® and collected by terminal bleeding 10 days post 
3rd i.n. immunization.  
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Figure 36: CP0020-1 Immunofluorescence; A: HEp-2 cells 44 hours post infection; AI: anti-
Cp0585; AII: DAPI; AIII: anti-CP0020-1 serum; AIV: overlay; B: HEp-2 cells 44 hours post 
infection; BI: anti-Cp0585; BII: anti-CP0020-1 serum; BIII: DAPI; BIV: overlay; 3*105 HEp-
2 cells were plated on 13mm diameter glass slides in 24-well plates and incubated for 20 hours 
before infection with Cpn K6 at a MOI of 2. Subsequently HEp-2 cells were incubated for 44 
hours followed by immunofluorescent staining of the inclusion membrane, the respective 
antigen and DNA staining with DAPI. Sera were derived from mice immunized 3 times with 
CP0020-1 40 µg/mouse + IC31® and collected by terminal bleeding 10 days post 3rd i.p. 
immunization.  
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Sera derived from mice immunized with the recombinant C. pneumoniae 
antigen CP0177-1 did not show any reactivity at 44 h post infection (not 
shown). According to earlier studies dealing with CP0177 orthologs, in ad-
dition to the 44 hours time point, immunofluorescent staining of infected HEp-
2 cells was additionally performed at 1 hour post infection. Reaction of sera 
derived from animals, immunized 3 times i.p. with CP0177-1 in combination 
with IC31®, clearly showed to react with Cpn EBs at the earlier time point, 
which was corresponding to previous investigations [79, 90].   
Figure 35A+B show Cpn EBs visualized by anti-CP0177-1 reactivity located at 
the putative entry site of the Chlamydia. Interestingly, a co localized signal for 
Cp0585 was observed indicating the formation of the early inclusion. 
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Figure 37: CP0504 Immunofluorescence; A: HEp-2 cells 1 hour post infection; AI: anti-
Cp0585 (white); AII: anti-CP0504 serum; AIII: DAPI; AIV: overlay; B: uninfected HEp-2 
cells; BI: anti-Cp0585 (white); BII: anti-CP0504 serum; BIII: DAPI; BIV: overlay; 1.5*105 
HEp-2 cells were plated on 13mm diameter glass slides in 24-well plates and incubated for 21 
hours before infection with Cpn K6 at a MOI of 2. Subsequently HEp-2 cells were incubated 
for 1 hour followed by immunofluorescent staining of the inclusion membrane, the respective 
antigen and DNA staining with DAPI. Sera were derived from mice immunized 3 times with 
CP0504 40 µg /mouse + IC31® and collected by terminal bleeding 10 days post 3rd i.n. 
immunization.  
 
Sera of CP0020-1 immunized BALB/c mice showed to react with Cpn RBs at 
44 hours post infection (figure 36A+B). Furthermore reaction with Cpn EBs 
was observed at this time point, but seemed less strong than seen for RBs. 
Immunofluorescent control straining of uninfected HEp-2 cells using sera 
derived from CP0177-1 and CP0020-1 immunized animals are shown in figure 
40B+C respectively.  
The signals obtained with anti-CP0504 and anti-CP0879 sera both 
suggest a specific reaction with Cpn EBs at 1 hour post infection, while 
unspecific reactivity seemed stronger with sera from CP0879 immunized 
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animals. No specific signal was obtained for either antigen at 44 hours post 
infection using the same sera, which excludes the presence of these antigens on 
Cpn RBs (not shown). 
 I 
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Figure 38: CP0879 Immunofluorescence; A: HEp-2 cells 1 hour post infection; AI: anti-
Cp0585 (white); AII: anti-CP0879 serum; AIII: DAPI; AIV: overlay; B: uninfected HEp-2 
cells; BI: anti-Cp0585 (white); BII: anti-CP0504 serum; BIII: DAPI; BIV: overlay; 1.5*105 
HEp-2 cells were plated on 13mm diameter glass slides in 24-well plates and incubated for 21 
hours before infection with Cpn K6 at a MOI of 2. Subsequently HEp-2 cells were incubated 
for 1 hour followed by immunofluorescent staining of the inclusion membrane, the respective 
antigen and DNA staining with DAPI. Sera were derived from mice immunized 3 times with 
CP0879 40 µg /mouse + IC31® and collected by terminal bleeding 6 days post 3rd i.n. 
immunization.  
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Figure 39: CP0409 Immunofluorescence; A: HEp-2 cells 44 hours post infection; AI: anti-
Cp0585 (red); AII: DAPI; AIII: anti-CP0409 serum; AIV: overlay; B: uninfected HEp-2 cells; 
BI: anti-Cp0585 (red); BII: anti-CP0409 serum; BIII: DAPI; BIV: overlay; 3*105 HEp-2 cells 
were plated on 13mm diameter glass slides in 24-well plates and incubated for 21 hours before 
infection with Cpn K6 at a MOI of 2. Subsequently HEp-2 cells were incubated for 44 hours 
followed by immunofluorescent staining of the inclusion membrane, the respective antigen and 
DNA staining with DAPI. Sera were derived from mice immunized 3 times with CP0020-1 40 
µg/mouse + IC31® and collected by terminal bleeding 6 days post 3rd i.n. immunization.  
 
CP0409 was found to be located on both Cpn RBs and Cpn EBs, as 
signals obtained at 44 hours post infection did show (figure 39A), though 
reactivity with EBs seemed inferior. Furthermore, weak unspecific reactivity of 
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these sera, located at the cytoplasm of HEp-2 cells, was observed in uninfected 
samples (figure 39B). 
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Figure 40: CP0529, CP0177-1, CP0020-1, Adjuvant controls; Immunofluorescence; A: 
uninfected HEp-2 cells; AI: anti-Cp0585 (red); AII: anti-CP0529 serum; AIII: DAPI; AIV: 
overlay; B: uninfected HEp-2 cells; BI: anti-Cp0585 (red); BII: anti-CP0177-1 serum; BIII: 
DAPI; BIV: overlay; C: uninfected HEp-2 cells; CI: anti-Cp0508; CII: anti-CP0020-1 serum; 
CIII: DAPI; CIV: overlay; D: HEp-2 cells 44 hours post infection; DI: anti-Cp0508; DII: anti-
IC31® serum; DIII: DAPI; DIV: overlay; A, C: 3*105 HEp-2 cells were plated on 13mm 
diameter glass slides in 24-well plates and incubated for 20 hours. Immunofluorescent staining 
of the inclusion membrane, the respective antigen and DNA staining with DAPI was 
performed after another incubation period of 44 hours. B: 1.5*105 HEp-2 cells were plated on 
13 mm diameter glass slides in 24-well plates and incubated for 21 hours. Immunofluorescent 
staining of the inclusion membrane, the respective antigen and DNA staining with DAPI was 
performed after another incubation period of 1 hour. D: 1.5*105 HEp-2 cells were plated on  
13 mm diameter glass slides in 24-well plates and incubated for 21 hours before infection with 
Cpn K6 at a MOI of 2. Subsequently HEp-2 cells were incubated for 44 hours followed by 
immunofluorescent staining of the inclusion membrane, the respective antigen and DNA 
staining with DAPI.  Sera were derived from mice immunized 3 times with A: CP0529 
40 µg/mouse + IC31® i.p.; B: CP0177-1 40 µg/mouse + IC31® i.n.; C: CP0020-1 40 µg/mouse 
+ IC31® i.p.; D: IC31® (20/0.8) only i.n. All sera were obtained 10 days post 3rd immunization 
by terminal bleeding. 
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Figure 40D shows an immunofluorescent staining of Cpn K6 infected HEp-2 
cells using sera from BALB/c mice immunized 3 times i.n. with the adjuvant 
IC31® alone. Slight unspecific reactivity was observed in the green (anti-
IC31®) channel.  
In general, immunizations of mice with the diverse Cpn antigens in 
combination with IC31® resulted in superior intensities of signals in 
immunofluorescence microscopy compared to signals obtained from sera of 
mice immunized with the antigen alone. This was especially observed when 
sera from intra nasal immunizations were used as primary antibodies.  
Exceptions were candidate antigens CP0409 and CP0020-1, which gave 
comparable intensities when administered to mice with and without 
adjuvantation. Furthermore, intra peritoneal immunizations led to a higher 
specificity of antibody reaction in immunofluorescence assays compared to 
intra nasal immunizations, as the later showed an overall greater tendency for 
unspecific reactions (own observations). 
 
 
5 Discussion 
 
The application of the AIP® technology to various human pathogens has 
already led in the past to the identification of promising novel subunit vaccine 
candidates. The results of this study demonstrated that also in the case of C. 
pneumoniae the serological antigen identification on a genome-wide basis is an 
efficient tool for the discovery of antigenic proteins that are furthermore in the 
majority highly immunogenic and potentially protective.  
 Regarding the adjuvantive effect of IC31® in combination with the 
diverse recombinant Cpn antigens, which were selected on the basis of the 
results obtained by the AIP® technology, the data obtained during this study 
strongly supports the efficacy and efficiency of this adjuvant in mucosal 
applications. In general IC31® strongly improved the immunogenicity of the 
tested recombinant proteins by enhancing the production of the type 1 
interferon IFN-γ as well as antigen specific immunoglobulin responses and 
induction of CD154 cell marker on CD4+ T cells. Importantly the adjuvantive 
effect of IC31® was observed in local as well as systemic compartments 
following intra nasal application. Several findings, besides the improved IFN-γ 
production, support the dominating type 1 immune response-inducing effect of 
IC31®: No substantial enhancing effect on IL-4 secretion was observed 
comparing adjuvanted and antigen-alone immunizations. The secretion of IL-4 
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in response to restimulation of spleen cells derived from mice immunized i.p. 
with IC31®-adjuvanted CP0529, for which strong TH2-type stimulatory 
properties were identified, was even reduced compared to the experimental 
group that had received the protein antigen alone. Furthermore, the protective 
effect of those antigens which showed to have a significant influence on the 
reduction of bacterial loads (CP0529, CP0177-1, CP0020-1, CP0504) in the 
lungs of Cpn K6 challenged animals, where the importance of the induction of 
type 1 immune responses for protection is generally accepted, was improved by 
the co administration of  the adjuvant IC31®. Though, intern differences at 
experimental groups immunized with the antigens CP0020-1 and CP0529 
where not significant. Additionally, intra nasal immunization of BALB/c mice 
with the well characterized Cpn T cell antigen CopN in combination with 
IC31® showed to have a substantial reductive impact on the bacterial burden in 
murine lungs during challenge studies. Importantly, intra nasal administration 
of IC31® alone did not influence the outcome of challenge experiments nor 
were any toxic effects observed in experimental groups that had received this 
adjuvant.  
 In more detail, each of the 6 selected Cpn antigens showed its own 
pattern of immune responses directed against the particular protein, following 
immunization with the purified antigen, as well as in infection primed immune 
response studies. The results of both antigen specific immune responses were 
correlated to the data obtained in Cpn challenge experiments.  
CP0529 protein, which was found to be located on Cpn RBs but not 
EBs by immunofluorescence microscopy, was not immunogenic in terms of 
IFN-γ production as evaluated by ELIspot from murine splenic lymphocytes 
when delivered via the intra nasal route and additionally failed to elicit 
systemic immune responses in terms of CD154 upregulation on splenic CD4+ 
T cells. On the other side, intra nasal administration of this protein antigen led 
to the upregulation of CD154 in local compartments and elicited strong 
immunoglobulin responses of the IgG isotype but failed to evoke antigen 
specific serum IgA. Infection primed immune responses directed against 
CP0529 revealed a similar picture, as no antigen specific IgA but only IgG 
could be detected in serum of infected/reinfected BALB/c and at a lower level 
in C57BL/6 mice. However, i.n. immunization of BALB/c mice with CP0529 
did show to have a significant but modest effect on the number of IFUs in 
lungs derived from Cpn challenged animals, most probably induced by a strong 
local TH2-type response. Altogether CP0529 is not a preferable vaccine 
candidate.  
This statement is also true for candidates CP0409, CP0879 and  
candidate CP0504. CP0409 showed a general low immunogenicity as well as 
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an in this case undesired preferential induction of TH2-type immune responses. 
Similar to CP0529, CP0409 was recognized during Cpn infection in BALB/c 
but not in C57BL/6 mice as assessed by cultured IFN-γ ELIspot, further 
supporting the TH2 driven responses to these antigens. CP0879, a protein most 
probably located on Cpn EBs but not present in Cpn RBs did not reduce 
bacterial loads in lungs of intra nasally challenged BALB/c mice, though 
vaccination with the adjuvanted recombinant protein showed promising results 
in cellular and humoral immune response experiments. However, as CP0879 
was only recognized in a low amount by antibodies but no antigen specific 
IFN-γ responses were seen in infection primed immune response studies, most 
probably this antigen is not able to induce protective T cell responses due to 
low exposure/accessibility. The unspecific induction of IFN-γ production, in 
response to restimulation with the whole protein, in these experiments was 
most probably due to the in comparison high level of LPS (182.58 EU/mg) 
present in the preparation of CP0879 recombinant protein. 
 Candidate CP0504, which gave similar results in immunofluorescence 
microscopy as CP0879, indicating the presence of this protein on Cpn EBs, but 
not RBs, was found to have a significant reductive effect on the bacterial 
burden in the lungs of Cpn K6 challenged animals when administered intra 
nasally in combination with the adjuvant IC31®. As assessed in infection 
primed immune response studies, CP0504 was recognized during Cpn K6 
infection in both investigated mouse strains, indicated by systemic antigen 
specific IFN-γ responses as well as serum IgG and serum IgA responses. 
Though the latter was only found in C57BL/6 mice. In general the results 
obtained for candidate CP0504 during this study were quite encouraging but 2 
protein candidates, namely CP0177-1 and CP0020-1, gave superior results in 
all evaluated criteria. 
 The conserved hypothetical protein CP0177-1 was identified by aa seq-
uence homology as the Ct TARP ortholog. Reaction of anti-CP0177-1 sera 
with Cpn K6 EBs was observed at 1 hour post infection at the putative entry 
site of the Chlamydia, which was consistent with previous studies reporting the 
presence of TARP on Cpn EBs at this time point [79]. The recombinant protein 
CP0177-1, as assessed in immunization studies, was not immunogenic. In 
contrast, when CP0177-1 was combined with the adjuvant IC31®, strong 
immunogenicity in terms of systemic IFN-γ responses as well as local and 
systemic antigen-induced upregulation of CD154 cell marker was observed 
following intra nasal delivery. Furthermore, intra nasal immunization of mice 
with adjuvanted CP0177-1 induced the production of serum IgG and serum 
IgA antigen specific antibodies. Correlative, CP0177-1 in combination with 
IC31® led to a dramatic reduction of IFUs in the lungs of challenged mice, 
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while immunization with the protein alone did not show this effect. Using the 
CP0177-1 peptide library, for a more precise analysis of T cell responses, did 
not reveal a protruding immunogenic epitope. However, a cluster of peptides 
leading to intensified IFN-γ responses in ELIspot from spleen cells of both, 
immunized and infected/reinfected BALB/c mice, could be identified. A more 
detailed picture might have been obtained if the concentration of stimuli would 
have been increased to 10 µg/ml, as in ELIspot assays 5 µg/ml of each peptide 
were used as stimulus. However, FCM proliferation experiments using CFSE-
CD3+-CD4+ staining revealed a strong inductive potential when spleen cells 
from CP0177-1 immunized animals were restimulated with 10 µg/ml of the 
whole protein. This potential was more pronounced in the group immunized in 
combination with the adjuvant IC31® and furthermore showed a greater 
induction of CD3+ CD4- T cells, which were most probably CD8+ T cells, in 
comparison to the experimental group which had received CP0177-1 alone. 
Peptide D1 (SILNFLKNPAVQQKM) was the only 15-mer identified as a 
positive stimulator of IFN-γ in ELIspots from immunized and infected/ 
reinfected BALB/c mice as well as in proliferation experiments, though 
responses were weak. Interestingly, peptides G2 and G3 showed strong 
induction of T cell proliferation following restimulation of spleen cells derived 
from mice immunized with adjuvanted CP0177-1, but did not stimulate IFN-γ 
responses. This T cell population may be composed of IL-4 secreting CD4+ T 
cells and/or T-helper 17 cells, a subclass of CD4+ T cells that is characterized 
by IL-23 and IL-17 secretion but not IFN-γ, and which has been found to be 
critical to augmenting recruitment of TH1 cells in M. tuberculosis pulmonary 
infection as well as playing critical roles in mediating host mucosal immunity 
to a number of other pulmonary pathogens such as the Gram-negative bacteria 
P. aeroginosa and K. pneumoniae [92, 93]. 
 Further support for the induction of TH17 cells in response to CP0177-1 
come from cytokine bead assay experiments where upon in vitro restimulation 
of spleen cells, which were derived from BALB/c mice 10 days post 3rd i.p. 
immunization, a substantial increase of IL-17 in culture supernatants was 
observed (not shown). IL-17 production in these experiments was even more 
pronounced in the group immunized with IC31®-adjuvanted CP0177-1, while 
IC31®-alone immunized and naïve mice did not show this effect. A potential 
source for the higher induction of IL-17 in experimental groups immunized 
with adjuvanted antigen are activated DCs that secrete IL-23 and thereby 
indirectly induce IL-17 production.  
Regarding the role of IL-17 in chlamydial infection, various studies 
demonstrated the importance of this cytokine in initiating protective host 
immune response mechanisms in a pulmonary C. muridarum infection model 
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by for example promoting type 1 T cell immunity through the modulation of 
DC function [94-96]. However, further investigations respecting the role of IL-
17 in intracellular bacterial infection are necessary in order to obtain a more 
conclusive picture about the importance of TH17 cells in protection against 
Chlamydia infection as well as inflammatory pathologies associated with 
disease caused by Chlamydia. 
CP0020-1 protein was the second highly immunogenic antigen which 
additionally revealed a distinctive protective effect in the process of this study. 
Regarding immunogenicity of CP0020-1, studies in BALB/c mice showed a 
substantial induction of IFN-γ in systemic compartments following intra nasal 
delivery of this antigen, as well as strong upregulation of CD154 cell marker 
on CD4+ T cells derived from lungs and spleens of these animals. Interestingly, 
immunizations with CP0020-1 elicited strong antibody responses as evaluated 
in terms of serum IgG and serum IgA titers, which were in comparison less 
dependent on the adjuvant IC31® than observed with the other investigated 
antigens, indicating high CD4+ T cell stimulatory properties of this Cpn 
antigen. Respecting i.n. Cpn infection primed immune responses, antigen 
specific IFN-γ responses induced by CP0020-1 were observed in both 
investigated mouse strains, while IFN-γ levels were clearly higher in BALB/c 
mice which was most probably due to the strong antigenic properties of 
CP0020-1. Furthermore, Cpn infection evoked high titers of CP0020-1 specific 
serum IgG and serum IgA.  Correlative to the pronounced immune responses 
observed in experimental groups immunized i.n. with the antigen CP0020-1, 
either in combination with the adjuvant IC31® or with the protein alone, a 
substantial reductive effect on the number of IFUs in lungs of challenged 
BALB/c mice was observed in both groups in two independent experiments. 
Using sera from immunized BALB/c mice CP0020-1 was localized by 
immunofluorescence microscopy on Cpn RBs and EBs, while reaction seemed 
weaker with EBs.   
As for CP0177-1, a peptide library consisting of 15-mers spanning the 
entire sequence of the CP0020-1 protein and overlapping by 10 residues was 
generated in order to evaluate T cell responses in more detail, as well as in 
order to identify immunogenic epitopes. As found by IFN-γ ELIspot using 
spleens from s.c. and i.d. immunized BALB/c mice, 5 immunogenic peptides 
were identified. Out of these 5, only peptide A11 additionally showed to elicit 
IFN-γ responses in mice immunized with the protein alone, though IFN-γ 
levels were dramatically lower than observed in mice that had received the 
adjuvanted protein. However, only peptides D9 (QGVLTPEQFTIFAEI) and 
D10 (PEQFTIFAEIATELQ) furthermore evoked IFN-γ responses during Cpn 
infection in BALB/c mice. Interestingly, peptides D3 (LAGKYGNQATLTQ 
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TF) and D4 (GNQATLTQTFADGRV) were immunogenic in infected/ 
reinfected C57BL/6 mice as evaluated by restimulation with 5 µg/ml of the 
respective 15-mer in IFN-γ ELIspot. Peptides A11, D9 and D10 were moreover 
identified as positive stimulators in proliferation assays using BALB/c mice. In 
respect to the analyzed T cell subpopulations, 15-mers D9 and D10 mainly 
induced proliferation of CD4+ T cells, while peptide A11 additionally induced 
proliferation in a CD3+ CD4- T cell population, which represented most 
probably CD8+ T cells. Regarding the induction of T cell proliferation by ex 
vivo restimulation with 10 µg/ml of the whole recombinant protein, both CD3+ 
CD4+ and CD3+ CD4- responses were observed. In contrast to CP0177-1, the 
induction of CD3+ CD4- T cell proliferation was also observed in the group 
immunized with CP0020-1 alone, indicating CD8+ stimulatory properties of 
CP0020-1. As with CP0177-1, peptide screening using the CFSE-CD3-CD4 
staining revealed 15-mers that stimulated T cell proliferation but which were 
not identified as stimulators of IFN-γ in ELIspots (A12, B1, G3, G8 and G9; 
not shown). As described before for protein CP0177-1, this T cell populations 
may be composed of IL-4 secreting CD4+ T cells and/or TH17 cells, as also for 
this antigen, high levels of IL-17 were detected in culture supernatants of T 
cells derived from spleens of i.p. immunized BALB/c mice after in vitro 
restimulation with CP0020-1 (not shown).  
In summary two promising subunit vaccine candidates could be 
identified in the course of this study, though peptide screenings for candidate 
CP0177-1 should be repeated using higher concentrations of in vitro stimuli in 
order to obtain a more distinguished idea about IFN-γ responses to immuno-
genic peptides. Furthermore, as here only partial constructs of the whole 
proteins were used for the evaluation of immunogenicity and immunization 
induced protection using IC31® as an adjuvant, subsequent studies should 
evaluate constructs consisting of the remaining partial sequences as well as the 
whole recombinant proteins CP0177 and CP0020, which exceeded the aims of 
this study. Such investigations would be especially interesting for protein 
CP0177 as the in Chlamydia highly conserved domain is located in the C-
terminal region of the protein. Therefore CP0177 represents a potential cross 
protective Cpn antigen. Furthermore such experiments have the potential for 
the identification of other immunogenic epitopes that could be part of a multi-
epitope vaccine built in the way it was previously designed by Pinchuk et al. 
[97], or otherwise of a subunit vaccine consisting of several protective antigens 
and additionally containing the two component adjuvant IC31® as a potent 
inducer of TH1-type immune responses in mucosal/nasal applications.  
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In spite of the encouraging results obtained for IC31® as a potential mucosal 
adjuvant during this study future experiments will have to show the 
applicability and efficacy in humans, thereby ultimately allowing the 
implication in the prevention of infectious human disease.  
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6 Materials and Methods 
 
6.1 Antigen purification 
 
6.1.1 Growth of E.coli BL21 Codon Plus and over expression of 6x His-tag 
Chlamydia pneumoniae proteins 
 
Glycerol stocks (10% Glycerol, Sigma) of E.coli BL21 Codon Plus containing 
the vector pET28B, carrying an insert of one of the Chlamydia pneumoniae 
proteins CP0529 (hypothetical protein, [Chlamydia pneumoniae AR39]), 
CP0177-1 (amino acid 1-380 of 755, hypothetical protein, [Chlamydia 
pneumoniae AR39]), CP0020-1 (amino acid 2-418 of 812, hypothetical 
protein, [Chlamydia pneumoniae AR39]), CP0504 (hypothetical protein, 
[Chlamydia pneumoniae AR39]), CP0879 (hypothetical protein, [Chlamydia 
pneumoniae AR39]) and CP0409 (hypothetical protein, [Chlamydia 
pneumoniae AR39]) with a C-terminal 6x His tag were used throughout this 
study. 
For the production of biomass, 100 ml of LB medium (PAA) were 
inoculated in a 500 ml flask by adding a bit of material scratched from the 
respective E.coli BL21 Codon Plus glycerol stock and incubated over night 
(o/n) at 37 °C and 180 rpm in a shaker, in the presence of 50mg/ml Kanamycin 
(Serva) and 50 mg/ml Chloramphenicol (Calbiochem). 
On the following day the 100 ml o/n culture was added to 2000 ml LB 
medium containing 50 mg/ml Kanamycin and incubation at 37 °C, 180 rpm 
was continued for 2 hours (OD600 = 0.3 – 0.5). At this point, 0.1 mM IPTG 
(Serva) was added for the induction of recombinant protein expression. The 
culture was further incubated for 4 hours at 37 °C, 180 rpm. Subsequent to this 
incubation period cells were harvested by centrifugation. The pellet was 
resuspended in 30 ml PBS (Gibco), transferred into a 50ml falcon and stored at 
-20 °C. 
 
6.1.2 Lysis 
 
Lysis of recombinant E.coli biomass was performed using the high pressure 
homogenizer (HPH) “Panda 2K”, manufactured by Niro-Soavi, in the presence 
of protease inhibitors (1 µg/ml Leupeptin (Serva), 1 µg/ml Pepstatin A 
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(Sigma), 1 µg/ml Aprotinin (Sigma), 40 µM Bestatin (Sigma), 10 µM E-64 
(Sigma) and 1000 µM AEBSF (Serva). 
Prior to lysis, the biomass was resuspended in 50 mM TrisHCl (Serva), pH 8.0, 
500 mM NaCl (Sigma), 1% TritonX-100 (Fluka) (final volume: 250 ml). 
Additionally 1 mM DTT (Serva) was added to those suspensions of E.coli 
biomass which expressed proteins containing > 2 cysteines.  
For the subsequent degradation of DNA, DNase I grade 2 (100 µg/ml, 
Sigma) and CaCl2 (1 mM, Fluka) were added to the crude lysate and incubated 
for 45 min at RT and 180 rpm. The soluble fraction of the lysate was separated 
from the insoluble fraction by centrifugation (10000 g, 10 min). 
For the assessment of protein expression a sample was taken from the 
crude lysate, the soluble fraction and the insoluble fraction followed by SDS-
PAGE analysis. 
Insoluble Proteins were further washed in 1 M Urea (Sigma), 50 mM 
TrisHCl, pH 8.0, 500 mM NaCl, 1% Triton X-100, 1 mM EDTA (Sigma) and 
10 mM DTT. For the estimation of the optimal washing condition a small 
portion was further washed with increasing concentrations of Urea (1 mM,  
2 mM and 3 mM) followed by analysis through SDS-PAGE. 
After washing the insoluble pellet twice in 10 x volume of the previously 
determined washing buffer the purified inclusion bodies were one time washed 
and subsequently resuspended in the final wash buffer, 50 mM TrisHCl, pH 
8.0, 150 mM NaCl, 1 mM EDTA, 0.5 mM DTT. 
 
6.1.3 SDS-PAGE 
 
For SDS-PAGE gold precast gradient gels containing 4-20% Polyacrylamid 
(Lonza) were used throughout this study. The Marker used for the estimation 
of molecular weights was the prestain protein ladder (Fermentas). For staining 
of protein bands the staining solution “SimplyBlue Safe Stain” (Invitrogen) 
was used. 
 
6.1.4 Soluble gravity column affinity purification 
 
Binding to Ni-sepahrose 6 fast flow (GE Healthcare) of soluble 6x His-tag 
recombinant protein was performed at 4 °C over night while rotating. 
1 ml of Ni-sepharose 6 fast flow was used for binding 10 mg of recombinant 
protein. 
Washing occurred with: 15 column volumes (CV) of buffer containing 
50 mM TrisHCl, pH 8.0, 500 mM NaCl, 0.1% Triton X-100 and 1 mM DTT 
followed by 10 CV 50 mM TrisHCl, pH 8.0, 500 mM NaCl, 1 mM DTT 
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followed by 5 CV 20 mM Imidazol (Sigma), 50 mM TrisHCl, pH 8.0, 500 mM 
NaCl and 1 mM DTT followed by 5 CV 40 mM Imidazol (Sigma), 50 mM 
TrisHCl, pH 8.0, 500 mM NaCl and 1 mM DTT 
Soluble Protein was eluted by washing with: 3 CV 250 mM Imidazol,  
50 mM TrisHCl, pH 8.0, 150 mM NaCl and 1 mM DTT 
Remaining insoluble protein was eluted by washing with: 3 CV 250 mM 
Imidazol, 50 mM TrisHCl, pH 8.0, 6 M GuaHCl (Sigma), 500 mM NaCl and  
1 mM DTT (note: for the isolation of CP0529 no DTT was added in any step) 
 
6.1.5 Insoluble gravity column affinity purification 
 
Inclusion bodies were denaturated by suspending the biomass in buffer 
containing 6 M GuaHCl, 50 mM Tris, pH 8.0, 500 mM NaCl, 0.1 %  
Triton X-100 and 1 mM DTT.  
Binding to Ni-sepahrose 6 fast flow (GE Healthcare) of soluble 6x His-
tag recombinant protein was performed at 4 °C over night while rotating. 1 ml 
of Ni-sepharose 6 fast flow was used for binding 10 mg of recombinant 
protein.  
Washing occurred with 10 CV 6 M GuaHCl, 50 mM TrisHCl, pH 8.0, 
500 mM NaCl, 0.1% Triton X-100 and 1 mM DTT followed by 
10 CV 6 M GuaHCl, 50 mM TrisHCl, pH 8.0, 500 mM NaCl and 1 mM DTT 
followed by 5 CV 20 mM Imidazol, 6 M GuaHCl, 50 mM TrisHCl, pH 8.0, 
500 mM NaCl and 1 mM DTT. 
Insoluble protein was eluted by washing with: 3 CV 250 mM Imidazol,  
6 M GuaHCl, 50 mM TrisHCl, pH 8.0, 500 mM NaCl, 1 mM DTT,  
0.1 % Tween20, 100 mM L-Arg (Serva) and 200 mM Sorbitol (Serva).  
 
6.1.6 Refolding 
 
Refolding conditions were tested for those insoluble proteins which showed 
precipitation during dialysis after gravity column purification. The optimal 
refolding buffer was assessed by diluting the eluted and denaturated protein 
1:50 in 10 different buffers varying in pH, L-Arg concentration and/or Urea 
concentration. This dilution was put on 4 °C o/n while shaking. 
On the subseqent day an aliquot of the soluble fraction of each buffer was 
analyzed by SDS-PAGE. The different protein bands were photographed using 
a CCD camera (Alpha Innotech) and compared by using the software “alpha 
view” (Alpha Innotech). The buffer which showed to have the largest amount 
of protein present in the soluble fraction was chosen for refolding and isolation. 
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 Refolding was performed by first changing the buffer to 8 M Urea, 50 mM 
TrisHCl, pH 8.0, 500 mM NaCl, 1 mM DTT and 0.1 % Tween20 by dialysis. 
This protein solution was then drop-wise diluted to 100 µg/ml at 4 °C while 
stirring, using the respective refolding buffer. 
After 12 hours Ni-Sepharose 6 fast flow beads were added to the soluble 
fraction of the solution (for the isolation of CP0409 the pH was changed from 
5.5 to 7.0 by adding NaOH prior to the addition of Ni-sepharose 6 fast flow). 
After letting the protein bind to the Ni-sepharose 6 fast flow beads for 12 
hours, isolation of the recombinant protein was performed by soluble gravity 
column purification. 
(note: prior to the elution of remaining insoluble protein a washing step with 3 
CV 250 mM Imidazol, 50 mM TrisHCl, respective pH, 150 mM NaCl, 1 mM 
DTT and 500 mM L-Arg was included). 
 
6.1.7 Dialysis 
 
Dialysis was performed over night at 4 °C on a magnetic stirrer. The volume of 
buffer was 100 x the sample volume. The dialysis buffer was changed two 
times in order to achieve full buffer change. Large sample volumes were 
dialyzed in dialysis soft tubes (Spectrum Labs), smaller volumes (< 10 ml) 
were dialyzed in dialysis cassettes (Slide-A-Lyzer, Thermo Scientific). 
 
6.1.8 BCA assay 
 
Protein concentration was determined using the BCA Protein Assay (Pierce) 
 
6.1.9 Western Blot “semidry” 
 
The marker used for Western Blot was the Magic marker XP (Invitrogen, 
“Western Standard”). The Tranfer Buffer concited of 39 mM Glycine, 48 mM 
Tris, 0.037% SDS (Serva), 20% Methanol (Merck). 
The Gelsandwich consisted of 3 pieces Whatman 3 mm-filter (Schleicher-
Schuell), followed by the Gel (gold precast gradient gel with 4-20% 
Polyacrylamid (Lonza)) and followed by 3 pieces Whatman 3 mm-filter 
(Schleicher-Schuell). Western Blot conditions were 15 V, 80 mA per gel, 1 
hour. 
After transfer, the NC-membrane (Immobilon-P, Millipore) was washed 
with MilliQ followed by staining with Ponceau S (Sigma) for 1-2 minutes. The 
membrane was destained by washing with MilliQ and subsequently blocked for 
1 hour with PBS containing 5% milk powder (Fluka). Incubation with primary 
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antibody (penta-his, BSA-free, mouse monoclonal IgG, 1:5000 in PBS, 1% 
Tween20, 5% milk powder) was performed at 4 °C o/n with gentle agitation. 
Subsequently the membrane was washed and incubated for 1 hour with the 
secondary antibody (Duko, polyclonal, rabbit anti-mouse HRP, 1:5000 in PBS, 
1% Tween20, 5% milk powder). 
After a washing step the developer solution Chemiglow substrate (Apha 
Innotech; “ChemiGlow West”) was added for 5 minutes. Pictures were 
acquired using a CCD camera (Alpha Innotech). 
 
 
6.1.10 LPS assay 
 
The amount of LPS-contamination was measured using the “PyroGene 
Recombinant Factor C endotoxin Detection System” (Lonza). 
 
6.1.11 LPS removal by filtration 
 
Mustang E Membrane filter (PALL) 
 
6.1.12 SEC analysis 
 
Size exclusion chromatography was performed by HPLC using a Superdex 200 
column with a runtime of 60 minutes and an injection volume of 50 µl 
measuring at the wavelength of 214nm. 
 
6.1.13 Concentration of isolated protein in final buffer 
 
Amicon Ultra 10K centrifugal filter unit (Millipore) 
 
6.1.14 Sterile filtration 
 
Prior to the final assessment of protein concentration, LPS contamination and 
the percentage of oligomerization the protein solution was 0.2 µm sterile 
filtered. 
 
6.1.16 Storage 
 
Protein solutions ready for immunization studies were stored at –80 °C. 
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6.2 Additional Antigens 
 
Chlamydia outer protein N (CopN, Low Calcium Response E [Chlamydophila 
pneumoniae CWL029]) with an N-terminal 6x His tag and Chlamydia major 
outer membrane protein (MOMP, ompA major Outer membrane protein 
[Chlmydophila pneumoniae CWL029]) with a C-terminal 6x His tag were used 
as control antigens during this study. In cultured ELIspots with splenocytes 
from Cpn K6 infected animals the in house identified Borrelia protein antigen 
BAP038 was used as irrelevant antigen for stimulation. 
The recombinant proteins were isolated in house by gravity column 
affinity purification from purified inclusion bodies after over expression in  
E. coli BL21 codon plus strain. The final buffer was 50 mM TrisHCl, pH 8.0, 
150 mM NaCl.  
 
6.3 Peptides for ex vivo restimulation 
 
The CP0177-1 and CP0020-1 peptide libraries used in this study consisted of 
15mers overlapping by ten residues covering the entire sequence of the 
recombinant protein. The peptides were synthesized in house by solid phase 
synthesis on preloaded 2-chlorotrityl resins (Pepchem) on a multiple peptide 
synthesizer (Syro, Multisyntech). Following synthesis, the peptides were 
cleaved from the resin and purified by RPHPLC. The identity and purity was 
confirmed by mass spectroscopy using a MALDI-TOF mass spectrometer 
Voyager-DE-STR (Applied Biosystems). All peptides were solubilized in 
DMSO (Sigma) to a concentration of 20 mg/mL. Peptides were stored at  
-20 °C. Peptides B8.1 (KYASGNSEI, CopN) and E8.1 (DYFESRVPI, CopN) 
were synthesized in house, solubilized and stored as described before. 
 
6.4 Mice 
 
Naïve female BALB/c (H2d) and C57BL/6 (H2b) mice were purchased from 
Charles River laboratories Germany at an age of 6-8 weeks. Mice were kept 
under specified pathogen free conditions with free access to water and food. 
Experiments were initiated before the mice reached the age of 12 weeks. All 
animal experiments were conducted according to Austrian law and approved 
by the Austrian Federal Ministry of Science and Research. 
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6.5 Adjuvants 
 
The classical preparation of IC31® in PBS (Gibco) was used throughout this 
study. KLKL5KLK (NH2-KLKLLLLLKLK-COOH) and ODN1a (phosphor-
diester backbone ODN, oligo-(dIdC)13) were purchased from Bachem (KLK) 
and Transgenomic (ODN1a). The single components of IC31® were mixed in 
PBS (pH = 7) at a molar ratio of 2000 nmol KLK / 80 nmol ODN1a  and stored 
at 4 °C. 
Before preparing the vaccine the IC31® preparation was vigorously 
mixed at room temperature. For intra nasal immunizations the amount of 
IC31® in the vaccine was 20 nmol KLK and 0.8 nmol ODN1a per mouse 
(IC31® (20/0.8)). For intra peritoneal, subcutaneous and intra dermal 
immunizations the amount of IC31® in the vaccine was 100 nmol KLK and 4 
nmol ODN1a per mouse (IC31® (100/4)). 
In some experiments Cholera toxin b subunit (Sigma) was used as an 
adjuvant for intra nasal vaccination of control groups. The amount given to 
each mouse of those groups was 10 µg. 
 
6.6 Vaccination of mice 
 
The amount of antigen delivered to each mouse irrespective of the route was  
40 µg. The volume for intra peritoneal injection was 200 µl. Subcutaneous 
injection combined with intra dermal injection was given at the tail base 
delivering each 100 µl. 
Intra nasal vaccination was performed using a pipette while keeping the 
mice under light anesthesia with Isofluorane (Baxter). The volume for intra 
nasal vaccination was 40 µl per mouse. Control groups either received adjuvant 
alone or were left naïve. .Vaccination occurred on day 0, 14 and 28 of each 
experiment. 
 
6.7 Infection of mice with Chlamydia pneumoniae K6 
 
The stock solution of Chlamydia pneumoniae Kajaani 6 (K6) purified 
elementary bodies was provided by Dr. Benjamin Wizel. The concentration in 
IFU/ ml of this stock was 3*108. Cpn K6 elementary body stocks were stored 
at -80 °C. Prior to intra nasal delivery the stock solution was diluted in ice cold 
PBS (Gibco). Each mouse received 1*106 IFU in a volume of 40 µl using a 
pipette, while keeping the mice under light anesthesia with Isoflurane (Baxter). 
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Intra nasal infection of mice in immunization-challenge studies was performed 
10 days following the 3rd vaccination. Infection priming of an immune 
response to Cpn K6 occurred by a primary intra nasal infection on day 0 of the 
experiment followed by a secondary intra nasal reinfection on day 30. 
 
6.8 Media 
 
For the isolation and in vitro incubation of splenocytes or total lung cells, 
defined T cell medium (TCM) was used throughout this study. TCM consisted 
of RPMI 1640 + L-glutamine (Gibco), 10% FCS (PAA), 20 mM HEPES 
(Gibco), 1 mM sodium pyruvate (PAA), 0.1 mM non essential amino acids 
(PAA), additional 2 mM L-glutamine (Gibco), 50 µM β-mercaptoethanol and  
100 units/ml penicillin and 100 μg/ml streptomycin (PAA). 
For the work with HEp-2 cells no β-mercaptoethanol was added to the 
medium. For the subsequent work with Chlamydia pneumoniae 100 µg/ml 
gentamycin was used instead of penicillin and streptomycin. This medium was 
defined as RPMI complete. For the incubation of Cpn K6 infected HEp-2 cells 
defined IMDM complete was used. This medium consisted of Iscove’s 
Modified Dulbecco’s Medium (Gibco), 10% FCS (PAA), 20 mM HEPES 
(Gibco), 1 mM sodium pyruvate (PAA), 0.1 mM non-essential amino acids 
(PAA), additional 2 mM L-glutamine (Gibco), 0.26 mg/mL sodium-
bicarbonate (PAA), 0.5 mg/mL glucose (Gibco) and 100 μg/mL gentamycin 
(PAA). 
 
6.9 Assessment of inclusion forming units (IFUs) in murine 
lungs 
 
Mice were sacrificed by cervical dislocation on day 10 after intra nasal 
challenge with Cpn K6. Lungs were removed and individually kept in each  
2 ml ice cold sucrose-phosphate-glutamic acid (SPG) buffer. Subsequently 
homogenates were prepared using an electrical homogenizer. Fat and tissue 
was separated from the fluid by centrifugation (1000 rpm, 10 min).  
The Supernatant was transferred into cryotubes and stored at -80°C.  
For the assessment of IFUs, HEp-2 cells were seeded on 13 mm diameter 
round glass slides (Thermo-Scientific) inside 24-well plates (Nunc) and 
incubated at 37 °C and 5% CO2 until a confluent monolayer was formed. 
Dilutions (1:50, 1:100 and 1:250) were prepared from individual lung 
homogenates in RPMI complete. For the infection of HEp-2 cells the medium 
was removed and 0.5 ml of the different dilutions were added in duplicates to 
 - 70 -    
the HEp-2 cells, followed by centrifugation at 550 g and 35 °C for 1 hour. 
Subsequent the medium was removed and 1.5 ml IMDM complete containing 
0.5 µg cycloheximide (Sigma) was added to each well. Infected HEp-2 cells 
were incubated for approximately 60 hours prior to immunofluorescent 
staining of C. pneumoniae inclusions. 
After washing with PBS (Gibco), cells were fixed by adding -20 °C cold 
methanol (Merck) fro 10 min. After another washing step, a blocking step with 
1% BSA in PBS was performed for 1 hour at RT. Following this blocking step, 
the primary antibody RR402 Mouse Mab anti-MOMP (B. Wizel), was added to 
each well. Incubation was performed at RT for 1 hour in a dark humid 
chamber. 
After washing with PBS (Gibco) the secondary antibody, AF488 Goat 
anti-mouse Ig (Invitrogen) was added. Incubation occurred at RT for 1 hour in 
a dark humid chamber. After another washing step the glass slides were 
carefully removed from the wells and put onto cover slips covered with 
Mowiol 4-88 (Sigma). Counting of fluorescently labeled inclusions was 
performed using an Axioplan 2 microscope (Zeiss).  
 
6.10 Cell preparation and purification 
 
10 days post 2nd and 3rd immunization as well as 10 days post reinfection, mice 
were sacrificed by cervical dislocation. Spleens and/or lungs were collected in 
each 8 ml of ice cold RPMI 1640 + L-glutamine (Gibco).  Spleens and/or lungs 
of the same experimental groups were pooled prior to mechanical preparation 
of the single cell suspension in RPMI 1640 + L-glutamine (Gibco). Reed blood 
cell lysis was performed in commercially available red blood cell lysis buffer 
(Sigma). Subsequently cells were washed in RPMI 1640 + L-glutamine 
(Gibco) and resuspended in TCM. Viable cell count was determined by trypan 
blue exclusion staining. 
 
6.11 Cultured IFN-γ ELIspot assay 
 
For culturing total spleen cells, quadruplicates of each experimental group 
containing 5*106 cells/well were incubated at 37 °C and 5% CO2  in sterile 24-
well plates (Nunc) in a volume of each 2 ml TCM for 48 hours in the presence 
of 5 µg/ml stimulus (relevant antigen, irrelevant antigen, medium). After this 
incubation period, cells of each experimental group were harvested by 
extensive washing with TCM and pooled. Subsequently viable cell count was 
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determined by trypan blue exclusion staining. The following procedure was 
performed as described in section 6.10 IFN-γ ELIspot assay. 
 
6.12 IFN-γ ELIspot assay 
 
For IFN-γ ELIspot assay sterile 96-well filtration plates were purchased from 
Millipore (Catalog number: MAHAS4510). Wells were pre-rinsed with PBS 
(Gibco) prior to the coating with the rat anti-mouse IFN-γ antibody (BD 
Pharmigen). The antibody was diluted to a concentration of 3 µg/ml in coating 
buffer. Coating buffer consisted of 0.1 M NaHCO3 in bidistilled water 
(Mayrhofer Pharmaceuticals) pH 9.2-9.4. Coating was performed o/n at 4 °C in 
a humid chamber. In advance of the assay plates were blocked with 1% BSA 
(PAA) in PBS (Gibco) at 37 °C for 1 hour.  
 Subsequent to the blocking step 0.25-1.0*106 cells in TCM were added 
in duplicates to each well. Additionally RACS (Becton Dickinson) was added 
to a final concentration of 1%. Finally stimuli were added. ConA (Sigma) was 
added as a positive control. TCM was used as negative control. Incubation 
occurred for approximately 20 hours at 37 °C and 5% CO2. 
Following incubation, plates were washed with washing buffer which 
consisted of 0.1% Tween20 (Sigma) in PBS (Gibco) for 15 minutes at RT. 
Secondary biotin anti-mouse IFN-γ antibody (BD Phrmigen) was diluted in 
PBS (Gibco) to a final concentration of 1 µg/ml and added to each well. 
Incubation occurred at 37 °C for 2 hours. After washing Streptavidin-labeled 
horseradish peroxidase (Roche) was added and incubated at 37 °C for 30 
minutes. After another washing-step, substrate was added, which consisted of 
0.8 mg/ml 3,3’diaminobenzidine, 0.4 mg/ml NiCl2 and 0.015% H2O2 in  
100 mM Tris. 
The reaction was performed at RT and was usually terminated after 
approximately 4-6 minutes, when visible spots had formed, by flushing the 
plates under cold tap water. Dry plates were analyzed with the Bioreader 5000 
(BioSys, Germany).  
 
6.13 IL-4 ELIspot assay 
 
IL-4 ELIspot was performed as described for IFN-γ ELIspot in section 6.10 
with the exception of not adding RACS after plating the cells. Multiscreen 
HTS filter plates were used for IL-4 ELIspot assays (Catalog number: MSIP 
S4510, Millipore). The rat anti-mouse IL-4 antibody (BD Pharmigen) was used 
as primary antibody at a final concentration of 2 µg/ml in coating buffer. The 
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secondary antibody, biotin anti-mouse IL-4 (BD Pharmigen), was diluted in 
blocking buffer to a final concentration of 1 µg/ml. 
 
6.14 Serum preparation and antigen-specific ELISA 
 
Terminal bleedings were collected 10 days post 2nd and 10 days post 3rd 
immunization or 10 days post reinfection, if not stated otherwise in the text.  
For the collection of blood Vacutainer SST tubes (Becton Dickinson) were 
used. Serum was prepared as described in the manufacturers’ manual and 
stored at -80 °C until needed. 
 For the estimation of the optimal coating concentration with antigen, 
each recombinant protein was titrated using serum from mice immunized with 
the relevant antigen and serum from mice immunized with an irrelevant 
antigen as well as sera from naïve mice as controls. The coating concentration 
which allowed the best differentiation between sera from mice immunized with 
the relevant antigen in comparison to sera from control groups was chosen for 
the subsequent antigen-specific ELISA. The selected coating concentrations 
were 1.25 µg/ml for CP0529, 0.63 µg/ml for CP0177-1, 2.5 µg/ml for  
CP0020-1, 0.63 µg/ml for CP0504, 2,5 µg/ml for CP0879, 1.25 µg/ml  
for CP0409, 0.31 µg/ml for CopN and 0,63 µg/ml for MOMP. 
 ELISA plates (Nunc Immuno plate F96 Maxisorp) were coated with  
50 µl of antigen diluted in PBS (Gibco) at 4 °C over night. Blocking was 
performed after flicking the liquid, by adding 100 µl/well 2% BSA (PAA) in 
PBS (Gibco) for 1.5 hours at 37 °C.  
The liquid was removed by flicking onto paper towels. Sera were serially 
diluted (as indicated in the text) in dilution buffer which consisted of 0.1% 
BSA (PAA) in PBS (Gibco). 50 µl of diluted serum was added to each well 
and incubation occurred for 1.5 hours at 37°C. Following plates were washed 3 
times with washing buffer which consisted of 0.1% Tween20 (Sigma) in PBS 
(Gibco). For the measurement of total serum IgG titers, polyclonal rabbit anti-
mouse immunoglobulin/HRP antibody (Dako Cytomation) was used. For the 
estimation of serum IgA titers, goat anti-mouse IgA/HRP antibody (Southern 
Biotech) was used. Secondary antibodies were diluted in dilution buffer and  
50 µl were added to each well. Incubation occurred for 1 hour at 37°C. 
Wells were washed 3 times with washing buffer before 50 µl of ABTS 
(Sigma) was added to each well. Plates were incubated for approximately  
20 minutes in the dark before measuring the color intensity at 405 nm on a 
Tecon Sunrise microplate reader. Using Graph Pad Prism 5 software 
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background subtraction and non linear regression was performed across all  
data points. 
 
6.15 Flow cytometry – surface staining 
 
Surface staining of cells isolated from murine spleens or lungs was performed 
by washing in FACS buffer followed by resuspension in 100 µl of FACS 
buffer containing 1 µg/ml rat IgG2a anti-mouse CD16/32 (eBioscience). 
Incubation occurred at RT for 20 min in the dark. After washing the cells in 
FACS buffer, cells were resuspended in 100 µl FACS buffer containing the 
appropriate antibody and incubated at RT, for 20 min in the dark. Antibodies 
used for surface staining in this study were 1 µg/ml rat IgG2a anti-mouse CD4 
FITC-conjugated antibody (eBioscience), 2 µg/ml Armenian hamster IgG anti-
mouse CD3 APC-conjugated antibody (eBioscience), 2µg/ml rat IgG2b anti-
mouse CD4 PE-Cy7-conjugated antibody (eBioscience) and respective isotype 
controls. Before measurement, cells were extensively washed and finally 
resuspended in FACS buffer. 
 
6.16 Flow cytometry - CD154 assay 
 
For the CD154 assay 1*106 cells derived from lung or spleen were plated in 
96-well U-bottom plates (Nunc), in TCM and a volume of 100 µl. 
Subsequently stimuli at a concentration of 10 µg/ml were added. As negative 
control, only medium was added. As positive control 1 µg/ml SEB (Sigma) 
was added to the respective well. Following stimulation, 1µg/ml GoligiStop 
(Becton Dickinson), 1.25 µg/ml Armenian hamster anti-mouse CD154 PE-
conjugated antibody (eBioscience) as well as respective isotype controls were 
added and cells were incubated for 6 hours at 37 °C and 5% CO2.  
 Anti-CD4 surface staining was performed as described in section 6.14.  
Cells were measured on a FACSCalibur equipped with CellQuest software. 
The data was analyzed using FCS Express 3 software (De Novo software). 
 
6.17 Flow cytometry - CFSE staining of splenocytes 
 
1*106 cells were plated in 96-well U-bottom plates (Nunc), in TCM in a 
volume of 100 µl. Cells were washed in PBS (Gibco) containing 5% FCS 
(PAA). CFSE staining was performed by carefully resuspending the cells in 
100 µl PBS (Gibco) containing 5% FCS (PAA) and 10 µM CFSE (Invitrogen) 
followed by incubation at 37 °C, 5% CO2 for 5 min. The reaction was stopped 
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by washing the cells with 5% FCS (PAA) in PBS (Gibco). Following another 
washing step cells were resuspended in 200 µl TCM containing the appropriate 
stimuli. Peptides and protein antigens were used at a concentration of  
10 µg/ml. TCM was used as negative control. 0.5 µg/ml ConA (Sigma) were 
used as positive control. Incubation occurred for 5 days at 37 °C and 5% CO2.
 Subsequent anti-CD3 combined with anti-CD4 surface staining was 
performed as described in section 6.15. Measurement was performed using the 
Cytomics FC 500 (Beckman Coulter). The data was analyzed using FCS 
Express 3 software (De Novo software) 
 
6.18 Immunofluorescence microscopy 
 
Infection of HEp-2 cells with Chlamydia pneumoniae K6 was performed as 
described in section 6.9 with the deviations in the incubation period prior to 
immunofluorescent staining (indicated in the text). Cpn K6 elementary bodies 
were added at a multiplicity of infection of 2. After removing the supernatatnt 
cells were washed with PBS (Gibco). Fixation was performed by the addition 
of 300 µl Cytofix/Cytoperm solution (BD Biosciences) and incubation for 20 
min at 4 °C. Cells were washed and subsequently blocking was performed by 
adding Perm/Wash solution (BD Biosciences) containing 1% BSA (PAA) 
followed by incubation for 1 hour at RT.  
Primary antibodies were sera from immunized animals, as mentioned in 
the text, and rabbit anti-Cpn0585 (B. Wizel). Antibodies were diluted in 
Perm/Wash solution (BD Biosciences) followed by incubation for 1 hour at RT 
in a dark, humid chamber. After washing, the secondary antibodies were 
diluted in Perm/Wash solution (BD Biosciences) and added. Secondary 
antibodies were AF488-conjugated goat anti-mouse IgG (Invitrogen) and 
AF594-conjugated goat anti-rabbit IgG (Invitrogen). Incubation was performed 
as before. Cover slips were subsequently washed and stained with 1 µg/ml 
DAPI for 10 minutes. After another washing step, cover slips were placed on 
glass slides and covered with Slowfade Gold (Invitrogen). Pictures were taken 
with an upright Laser Scanning Microscope LSM-510 Meta (Zeiss).  
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